U.S. patent application number 11/121873 was filed with the patent office on 2005-11-10 for arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-ht6 antagonists.
Invention is credited to Berger, Jacob, Zhao, Shu-Hai.
Application Number | 20050250943 11/121873 |
Document ID | / |
Family ID | 34965191 |
Filed Date | 2005-11-10 |
United States Patent
Application |
20050250943 |
Kind Code |
A1 |
Berger, Jacob ; et
al. |
November 10, 2005 |
Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as
5-HT6 antagonists
Abstract
Compounds of the formula I: 1 or pharmaceutically acceptable
salts, solvates or prodrugs thereof, wherein m, n, p, Ar, X,
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as
defined herein. Also provided are compositions comprising, methods
of preparing, and methods of using the subject compounds.
Inventors: |
Berger, Jacob; (Los Altos,
CA) ; Zhao, Shu-Hai; (Sunnyvale, CA) |
Correspondence
Address: |
ROCHE PALO ALTO LLC
PATENT LAW DEPT. M/S A2-250
3431 HILLVIEW AVENUE
PALO ALTO
CA
94304
US
|
Family ID: |
34965191 |
Appl. No.: |
11/121873 |
Filed: |
May 4, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60568314 |
May 5, 2004 |
|
|
|
Current U.S.
Class: |
544/105 ; 549/15;
549/350 |
Current CPC
Class: |
A61P 1/00 20180101; A61P
43/00 20180101; A61P 25/24 20180101; A61P 25/08 20180101; C07D
319/20 20130101; A61P 25/28 20180101; A61P 25/22 20180101; A61P
25/14 20180101; A61P 25/06 20180101; A61P 25/18 20180101; C07D
405/06 20130101; A61P 25/16 20180101; A61P 25/34 20180101; A61P
25/36 20180101; A61P 25/00 20180101; A61P 3/04 20180101; A61P 25/32
20180101 |
Class at
Publication: |
544/105 ;
549/015; 549/350 |
International
Class: |
C07D 265/36 |
Claims
What is claimed is:
1. A compound of formula I: 87or a pharmaceutically acceptable salt
thereof, wherein: m is from 0 to 3; n is from 1 to 3; p is from 0
to 3; Ar is optionally substituted aryl or optionally substituted
heteroaryl; X is --O--, --S-- or --NR.sup.a-- wherein R.sup.a is
hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl or C.sub.1-6
alkylsulfonyl; R.sup.1 and R.sup.2 each independently is hydrogen,
C.sub.1-6alkyl, C.sub.1-6alkoxy-C.sub.1-6alkyl, or
hydroxy-C.sub.1-6 alkyl; or one of R.sup.1 and R.sup.2 is hydrogen
or C.sub.1-6alkyl and the other is C.sub.1-6alkylcarbonyl,
C.sub.3-8 cycloalkyl, aryl-C.sub.1-6alkyl, hydroxy, or a five- or
six-membered heteroaryl or heterocyclyl that contains one or two
nitrogens; or R.sup.1 and R.sup.2 together with the nitrogen to
which they are attached may form a three- to seven-membered ring
that optionally contains an additional heteroatom selected from N,
O and S; or R.sup.1 and R.sup.2 together with the nitrogen to which
they are attached may form a guanidinyl group, an amidinyl group, a
carbamyl group, or a urea group; each R.sup.3 is independently
C.sub.1-6alkyl, hydroxy-C.sub.1-6alkyl or
C.sub.1-6alkoxy-C.sub.1-6alkyl; or two of R.sup.3 together with the
atoms to which they are attached may form a C.sub.4-6 carbocyclic
ring; or one of R.sup.3 together with one of R.sup.1 and R.sup.2
and the atoms to which they are attached may form a five or
six-membered ring; R.sup.4 and R.sup.5 each independently is
hydrogen or C.sub.1-6alkyl; or one of R.sup.4 and R.sup.5 together
with one of R.sup.1 and R.sup.2 and the atoms to which they are
attached may form a five or six-membered ring; or R.sup.4 and
R.sup.5together may form .dbd.NR.sup.f wherein R.sup.f is hydrogen
or C.sub.1-6alkyl; and each R.sup.6 is independently halo,
C.sub.1-6alkyl, halo-C.sub.1-6alkyl, hetero-C.sub.1-6alkyl, cyano,
--SO.sub.2R.sup.b, --C(.dbd.O)--NR.sup.cR.s- up.d, --SR.sup.c,
--C(.dbd.O)--R.sup.c, where each of R.sup.b, R.sup.c and R.sup.d is
independently hydrogen or C.sub.1-6alkyl.
2. The compound of claim 1, wherein X is --O--.
3. The compound of claim 1, wherein R.sup.4 and R.sup.5 are
hydrogen.
4. The compound of claim 1, wherein m is 0.
5. The compound of claim 1, wherein n is 1 or 2.
6. The compound of claim 1, wherein R.sup.1 and R.sup.2 each
independently is hydrogen or C.sub.1-6alkyl, or R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a three,
four, five or six-membered ring.
7. The compound of claim 1, wherein Ar is optionally substituted
phenyl.
8. The compound of claim 1, wherein p is 0.
9. The compound of claim 1, wherein said compound is of formula II:
88and wherein m, n, p, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5
and R.sup.6 are as recited in claim 1.
10. The compound of claim 9, wherein R.sup.4 and R.sup.5 are
hydrogen.
11. The compound of claim 10, wherein n is 1.
12. The compound of claim 11, wherein m is 0.
13. The compound of claim 1, wherein p is 0.
14. The compound of claim 13, wherein R.sup.1 and R.sup.2 each
independently is hydrogen or C.sub.1-6alkyl.
15. The compound of claim 14, wherein Ar is optionally substituted
phenyl.
16. The compound of claim 1, wherein said compound is of the
formula III: 89wherein: n is 1 or 2; q is from 0 to 4; each R.sup.7
is independently halo, C.sub.1-6alkyl, halo-C.sub.1-6alkyl,
hetero-C.sub.1-6alkyl, cyano, --SO.sub.2R.sup.b,
--C(.dbd.O)--NR.sup.cR.sup.d, --SR.sup.c, --C(.dbd.O)--R.sup.c,
where each of R.sup.b, R.sup.c and R.sup.d is independently
hydrogen or C.sub.1-6alkyl; and m, p, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 are as recited in claim 1.
17. The compound of claim 16, wherein q is 0.
18. The compound of claim 16, wherein q is 1 and R.sup.7 is
halo.
19. The compound of claim 16, wherein said compound is of the
formula IV: 90wherein n, p, q, R.sup.1, R.sup.2, R.sup.3, R.sup.6
and R.sup.7 are as recited in claim 16.
20. The compound of claim 16, wherein said compound is of the
formula V: 91wherein n, p, q, R.sup.1, R.sup.2, R.sup.3, R.sup.6
and R.sup.7 are as recited in claim 16.
21. The compound of claim 16, wherein said compound is of the
formula VI: 92wherein n, q, R.sup.1, R.sup.2 and R.sup.7 are as
recited in claim 16.
22. The compound of claim 16, wherein said compound is of the
formula VII: 93wherein n, q, R.sup.1, R.sup.2 and R.sup.7are as
recited in claim 16.
23. The compound of claim 21, wherein said compound is of formula
VIII: 94
24. The compound of claim 21, wherein said compound is of formula
IX: 95wherein q, R.sup.1, R.sup.2 and R.sup.7 are as recited in
claim 21.
25. The compound of claim 23, wherein: q is 0 or 1; R.sup.7 is
halo; and one of R.sup.1 and R.sup.2 is C.sub.1-6alkyl and the
other is hydrogen;
26. The compound of claim 9, wherein said compound is selected
from:
(+-)-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-a-
mine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-ylmethyl)-meth-
yl-amine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)--
methyl-amine;
(6-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmeth-
yl)-methyl-amine;
(6-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-yl-
methyl)-methyl-amine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-yl-
)-methylamine;
[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro-benzo[1,4]dioxin--
2-(S)-ylmethyl]-methyl-amine;
[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro-be-
nzo[1,4]dioxin-2-(R)-ylmethyl]-methyl-amine;
C-[7-(3-Fluoro-benzenesulfony-
l)-2,3-dihydro-benzo[1,4]dioxin-2-(S)-yl]-methyl amine;
1-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-pyrroli-
dine;
Benzyl-[7-(3-fluoro-benzenesulfonyl)-2,3-dihydro-benzo[1,4]dioxin-2--
ylmethyl]-amine;
Methyl-[7-(toluene-4-sulfonyl)-2,3-dihydro-benzo[1,4]diox-
in-2-ylmethyl]-amine;
Ethyl-[7-(3-fluoro-benzenesulfonyl)-2,3-dihydro-benz-
o[1,4]dioxin-2-ylmethyl]-amine;
[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro--
benzo[1,4]dioxin-2-ylmethyl]-dimethyl-amine;
[7-(3-Fluoro-benzenesulfonyl)-
-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl]-isopropyl-amine;
1-[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl]--
azetidine;
[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro-benzo[1,4]dioxin-2-yl-
methyl]-(2-methoxy-ethyl)-amine;
4-[7-(3-Fluoro-benzenesulfonyl)-2,3-dihyd-
ro-benzo[1,4]dioxin-2-ylmethyl]-morpholine;
1-(7-Benzenesulfonyl-2,3-dihyd-
ro-benzo[1,4]dioxin-2-ylmethyl)-azetidine;
1-[7-(3-Fluoro-benzenesulfonyl)-
-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl]-aziridine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-benzyl-amine;
C-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-yl)-methylamine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-dimethyl-amin-
e;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-isopropyl-a-
mine;
1-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-azirid-
ine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-(2-methox-
y-ethyl)-amine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl-
)-ethyl-amine;
Methyl-[7-(toluene-3-sulfonyl)-2,3-dihydro-benzo[1,4]dioxin-
-2-ylmethyl]-amine;
Methyl-[7-(toluene-2-sulfonyl)-2,3-dihydro-benzo[1,4]d-
ioxin-2-ylmethyl]-amine;
1-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-
-2-ylmethyl)-piperazine;
N-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-
-2-ylmethyl)-guanidine;
7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2,2-
'-spiro-3-pyrrolidine;
N-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-
-ylmethyl)-N-methyl-hydroxylamine;
1-(7-Benzenesulfonyl-2,3-dihydro-benzo[-
1,4]dioxin-2-ylmethyl)-1H-imidazole;
N-(7-Benzenesulfonyl-2,3-dihydro-benz-
o[1,4]dioxin-2-ylmethyl)-acetamide;
2-(3-Methylaminomethyl-2,3-dihydro-ben-
zo[1,4]dioxine-6-sulfonyl)-benzonitrile;
1-(7-Benzenesulfonyl-2,3-dihydro--
benzo[1,4]dioxin-2-ylmethyl)-pyrrolidin-3-ol;
3-(3-Methylaminomethyl-2,3-d-
ihydro-benzo[1,4]dioxine-6-sulfonyl)-benzonitrile;
(7-Benzenesulfonyl-2-me-
thyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amine;
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-urea;
[2-(6-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-yl)-ethyl]-methyl-am-
ine; and
[2-(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-yl)-ethyl]-m-
ethyl-amine.
27. A pharmaceutical composition comprising an effective amount of
the compound of claim 1 in admixture with a pharmaceutically
acceptable carrier.
28. A method for treating a central nervous system disease state in
a subject, said method comprising administering to said subject a
therapeutically effective amount of a compound of claim 1.
29. The method of claim 28, wherein the disease state is selected
from psychoses, schizophrenia, manic depressions, neurological
disorders, memory disorders, attention deficit disorder,
Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's
disease, food uptake disorders, and Huntington's disease.
30. A method for treating a disorder of the gastrointestinal tract
in a subject, said method comprising administering to said subject
a therapeutically effective amount of a compound of claim 1.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit under 35 U.S.C. 119(e) of
U.S. Provisional Application No. 60/568,314 filed May 05, 2004,
which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] This invention relates to substituted benzodioxane and
benzoxazine compounds, and associated compositions, methods for use
as therapeutic agents, and methods of preparation thereof.
BACKGROUND OF THE INVENTION
[0003] The actions of 5-hydroxytryptamine (5-HT) as a major
modulatory neurotransmitter in the brain are mediated through a
number of receptor families termed 5-HT1, 5-HT2, 5-HT3, 5-HT4,
5-HT5, 5-HT6, and 5-HT7. Based on a high level of 5-HT6 receptor
mRNA in the brain, it has been stated that the 5-HT6 receptor may
play a role in the pathology and treatment of central nerve system
disorders. In particular, 5-HT2-selective and 5-HT6 selective
ligands have been identified as potentially useful in the treatment
of certain CNS disorders such as Parkinson's disease, Huntington's
disease, anxiety, depression, manic depression, psychoses,
epilepsy, obsessive compulsive disorders, mood disorders, migraine,
Alzheimer's disease (enhancement of cognitive memory), sleep
disorders, feeding disorders such as anorexia, bulimia and obesity,
panic attacks, akathisia, attention deficit hyperactivity disorder
(ADHD), attention deficit disorder (ADD), withdrawal from drug
abuse such as cocaine, ethanol, nicotine and benzodiazepines,
schizophrenia, and also disorders associated with spinal trauma
and/or head injury such as hydrocephalus. Such compounds are also
expected to be of use in the treatment of certain gastrointestinal
(GI) disorders such as functional bowel disorder. See for example,
B. L. Roth et al., J. Pharmacol. Exp. Ther., 1994, 268, pages
1403-14120, D. R. Sibley et al., Mol. Pharmacol., 1993, 43,
320-327, A. J. Sleight et al., Neurotransmission, 1995, 11, 1-5,
and A. J. Sleight et al., Serotonin ID Research Alert, 1997, 2(3),
115-8.
[0004] While some 5-HT6 and 5-HT2A modulators have been disclosed,
there continues to be a need for compounds that are useful for
modulating the 5-HT6 receptor, the 5-HT2A receptor, or both.
SUMMARY
[0005] The invention provides compounds of the formula I: 2
[0006] or a pharmaceutically acceptable salt thereof, wherein:
[0007] m is from 0 to 3;
[0008] n is from 1 to 3;
[0009] p is from 0 to 3;
[0010] Ar is optionally substituted aryl or optionally substituted
heteroaryl;
[0011] X is --O--, --S-- or --NR.sup.a-- wherein R.sup.a is
hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl or
C.sub.1-6alkylsulfonyl;
[0012] R.sup.1 and R.sup.2 each independently is hydrogen,
C.sub.1-6alkyl, C.sub.1-6alkoxy-C.sub.1-6alkyl, or
hydroxy-C.sub.1-6alkyl;
[0013] or one of R.sup.1 and R.sup.2 is hydrogen or C.sub.1-6alkyl
and the other is C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl,
aryl-C.sub.1-6alkyl, or a five- or six-membered heteroaryl or
heterocyclyl that contains one or two nitrogens;
[0014] or R.sup.1 and R.sup.2 together with the nitrogen to which
they are attached may form a three- to seven-membered ring that
optionally contains an additional heteroatom selected from N, O and
S;
[0015] or R.sup.1 and R.sup.2 together with the nitrogen to which
they are attached may form a guanidinyl group, an amidinyl group, a
carbamyl group, or a urea group;
[0016] each R.sup.3 is independently C.sub.1-6alkyl,
hydroxy-C.sub.1-6alkyl or C.sub.1-6alkoxy-C.sub.1-6alkyl;
[0017] or two of R.sup.3 together with the atoms to which they are
attached may form a C.sub.4-6carbocyclic ring;
[0018] or one of R.sup.3 together with one of R.sup.1 and R.sup.2
and the atoms to which they are attached may form a five or
six-membered ring;
[0019] R.sup.4 and R.sup.5 each independently is hydrogen or
C.sub.1-6alkyl;
[0020] or one of R.sup.4 and R.sup.5 together with one of R.sup.1
and R.sup.2 and the atoms to which they are attached may form a
five or six-membered ring;
[0021] or R.sup.4 and R.sup.5 together may form an imino group of
the formula .dbd.NR.sup.f wherein R.sup.f is hydrogen or
C.sub.1-6alkyl; and
[0022] each R.sup.6 is independently halo, C.sub.1-6alkyl,
halo-C.sub.1-6alkyl, hetero-C.sub.1-6alkyl, cyano,
--SO.sub.2R.sup.b, --C(.dbd.O)--NR.sup.cR.sup.d, --SR.sup.c,
--C(.dbd.O)--R.sup.c, where each of R.sup.b, R.sup.c and R.sup.d is
independently hydrogen or C.sub.1-6alkyl.
[0023] The invention also provides methods for preparing the
aforementioned compounds. The subject methods may comprise, in
certain embodiments, reacting a compound of the formula 1c: 3
[0024] wherein n, p, Ar, R.sup.3 and R.sup.6 are as defined
herein,
[0025] with an amine of formula g:
R.sup.1R.sup.2NH g;
[0026] wherein R.sup.1 and R.sup.2 are as defined herein, to form a
compound of formula 1d: 4
[0027] The invention further provides compositions comprising, and
methods for using the aforementioned compounds.
DETAILED DESCRIPTION OF THE INVENTION
[0028] The invention provides substituted quinolinone compounds,
associated compositions, methods for use as therapeutic agents, and
methods of preparation thereof. In specific embodiments the
invention provides piperazinyl-substituted quinolinone compounds
and associated pharmaceutical compositions, and methods for using
the same in the treatment of central nervous system (CNS) diseases
and gastrointestinal tract disorders.
[0029] All patents and publications cited in this disclosure are
incorporated herein by reference in their entirety.
DEFINITIONS
[0030] Unless otherwise stated, the following terms used in this
Application, including the specification and claims, have the
definitions given below. It must be noted that, as used in the
specification and the appended claims, the singular forms "a",
"an," and "the" include plural referents unless the context clearly
dictates otherwise.
[0031] "Agonist" refers to a compound that enhances the activity of
another compound or receptor site.
[0032] "Alkyl" means the monovalent linear or branched saturated
hydrocarbon moiety, consisting solely of carbon and hydrogen atoms,
having from one to twelve carbon atoms. "Lower alkyl" refers to an
alkyl group or moiety of one to six carbon atoms, i.e.
C.sub.1-C.sub.6alkyl. Examples of alkyl groups include, but are not
limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl,
tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.
[0033] "Alkylene" means a linear saturated divalent hydrocarbon
radical of one to six carbon atoms or a branched saturated divalent
hydrocarbon radical of three to six carbon atoms, e.g., methylene,
ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene,
butylene, pentylene, and the like.
[0034] "Alkenylene" means a linear unsaturated divalent hydrocarbon
radical of two to six carbon atoms or a branched saturated divalent
hydrocarbon radical of three to six carbon atoms, e.g., ethenylene
(--CH.dbd.CH--), 2,2-dimethylethenylene, propenylene,
2-methylpropenylene, butenylene, pentenylene, and the like.
[0035] "Alkoxy" means a moiety of the formula --OR, wherein R is an
alkyl moiety as defined herein. Examples of alkoxy moieties
include, but are not limited to, methoxy, ethoxy, isopropoxy, and
the like.
[0036] "Alkoxyalkyl" means a moiety of the formula --R'--R", where
R' is alkylene and R" is alkoxy as defined herein. Exemplary
alkoxyalkyl groups include, by way of example, 2-methoxyethyl,
3-methoxypropyl, 1-methyl-2-methoxyethyl,
1-(2-methoxyethyl)-3-methoxypropyl, and
1-(2-methoxyethyl)-3-methoxypropyl.
[0037] "Alkylcarbonyl" means a moiety of the formula --R'--R",
where R' is oxo and R" is alkyl as defined herein.
[0038] "Alkylsulfonyl" means a moiety of the formula --R'--R",
where R.sup.1 is --SO.sub.2-- and R" is alkyl as defined
herein.
[0039] "Alkylsulfonylalkyl" means a moiety of the formula
R.sup.a--SO.sub.2--R.sup.b--, where R.sup.a is alkyl and R.sup.b is
alkylene as defined herein. Exemplary alkylsulfonylalkyl groups
include, by way of example, 3-methanesulfonylpropyl,
2-methanesulfonylethyl, 2-methanesulfonylpropy, and the like.
[0040] "Aminoalkyl" means a group --R--R' wherein R' is amino and R
is alkylene as defined herein. "Aminoalkyl" includes aminomethyl,
aminoethyl, 1-aminopropyl, 2-aminopropyl, and the like. The amino
moiety of "aminoalkyl" may be substituted once or twice with alkyl
to provide "alkylaminoalkyl" and "dialkylaminoalkyl" respectively.
"Alkylaminoalkyl" includes methylaminomethyl, methylaminoethyl,
methylaminopropyl, ethylaminoethyl and the like.
"Dialkylaminoalkyl" includes dimethylaminomethyl,
dimethylaminoethyl, dimethylaminopropyl,
N-methyl-N-ethylaminoethyl, and the like.
[0041] "Amidinyl" means a group of the formula: 5
[0042] wherein each R independently is hydrogen or alkyl as defined
herein.
[0043] "Amidinylalkyl" means a group --R--R' wherein R' is amidinyl
as defined herein and R is alkylene.
[0044] "Amido" means a group --C(O)--NRR' wherein R and R' each
independently is hydrogen or alkyl.
[0045] "Antagonist" refers to a compound that diminishes or
prevents the action of another compound or receptor site.
[0046] "Aryl" means a monovalent cyclic aromatic hydrocarbon moiety
consisting of a mono-, bi- or tricyclic aromatic ring. The aryl
group can be optionally substituted as defined herein. Examples of
aryl moieties include, but are not limited to, optionally
substituted phenyl, naphthyl, phenanthryl, fluorenyl, indenyl,
pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl,
aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl,
diphenylisopropylidenyl, benzodioxanyl, benzofuranyl,
benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl,
benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl,
benzomorpholinyl, methylenedioxyphenyl, ethylenedioxyphenyl, and
the like, including partially hydrogenated derivatives thereof.
[0047] "Aryloxy" means a moiety of the formula --OR, wherein R is
an aryl moiety as defined herein.
[0048] "Arylalkyl" and "Aralkyl", which may be used
interchangeably, mean a radical-R.sup.aR.sup.b where R.sup.a is an
alkylene group and R.sup.b is an aryl group as defined herein;
e.g., phenylalkyls such as benzyl, phenylethyl,
3-(3-chlorophenyl)-2-methylpentyl, and the like are examples of
arylalkyl.
[0049] "Aralkoxy" means a moiety of the formula --OR, wherein R is
an aralkyl moiety as defined herein.
[0050] "Carbamyl means a group of the formula: 6
[0051] wherein R.sup.g and R.sup.h each independently is hydrogen
or alkyl.
[0052] "Cyanoalkyl" means a moiety of the formula --R'--R", where
R' is alkylene as defined herein and R" is cyano or nitrile.
[0053] "Cycloalkyl" means a monovalent saturated carbocyclic moiety
consisting of mono- or bicyclic rings. Cycloalkyl can optionally be
substituted with one or more substituents, wherein each substituent
is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino,
monoalkylamino, or dialkylamino, unless otherwise specifically
indicated. Examples of cycloalkyl moieties include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, and the like, including partially unsaturated
derivatives thereof.
[0054] "Cycloalkylalkyl" means a moiety of the formula --R'--R",
where R' is alkylene and R" is cycloalkyl as defined herein.
[0055] "Guanidinyl" as used herein means a group of the formula:
7
[0056] wherein R, R', R" and R'" each independently is hydrogen or
alkyl.
[0057] "Heteroalkyl" means an alkyl radical as defined herein
wherein one, two or three hydrogen atoms have been replaced with a
substituent independently selected from the group consisting of
--OR.sup.a, --NR.sup.bR.sup.c, and --S(O).sub.nR.sup.d (where n is
an integer from 0 to 2), with the understanding that the point of
attachment of the heteroalkyl radical is through a carbon atom,
wherein R.sup.a is hydrogen, acyl, alkyl, cycloalkyl, or
cycloalkylalkyl; R.sup.b and R.sup.c are independently of each
other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; and
when n is 0, R.sup.d is hydrogen, alkyl, cycloalkyl, or
cycloalkylalkyl, and when n is 1 or 2, R.sup.d is alkyl,
cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or
dialkylamino. Representative examples include, but are not limited
to, 2-hydroxyethyl, 3-hydroxypropyl,
2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxypropyl,
1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl,
2-hydroxy-1-methylpropyl, 2-aminoethyl, 3-aminopropyl,
2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl,
aminosulfonylpropyl, methylaminosulfonylmethyl,
methylaminosulfonylethyl, methylaminosulfonylpropyl, and the
like.
[0058] "Heteroaryl" means a monocyclic or bicyclic radical of 5 to
12 ring atoms having at least one aromatic ring containing one,
two, or three ring heteroatoms selected from N, 0, or S, the
remaining ring atoms being C, with the understanding that the
attachment point of the heteroaryl radical will be on an aromatic
ring. The heteroaryl ring may be optionally substituted as defined
herein. Examples of heteroaryl moieties include, but are not
limited to, optionally substituted imidazolyl, oxazolyl,
isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl,
pyrazinyl, thienyl, benzothienyl, thiophenyl, furanyl, pyranyl,
pyridyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl,
benzofuryl, benzothiophenyl, benzothiopyranyl, benzimidazolyl,
benzooxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl,
benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl,
quinoxalinyl, purinyl, quinazolinyl, quinolizinyl, naphthyridinyl,
pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and the
like, including partially hydrogenated derivatives thereof.
[0059] "Heteroaryloxy" means a moiety of the formula --OR, wherein
R is a heteroaryl moiety as defined herein.
[0060] "Heteroarylalkyl" and "Heteroaralkyl", which may be used
interchangeably, mean a radical-R.sup.aR.sup.b where R.sup.a is an
alkylene group and R.sup.b is a heteroaryl group as defined
herein.
[0061] "Heteroaralkoxy" means a moiety of the formula --OR, wherein
R is a heteroaralkyl moiety as defined herein.
[0062] The terms "halo" and "halogen", which may be used
interchangeably, refer to a substituent fluoro, chloro, bromo, or
iodo.
[0063] "Haloalkyl" means alkyl as defined herein in which one or
more hydrogen has been replaced with same or different halogen.
Exemplary haloalkyls include --CH.sub.2Cl, --CH.sub.2CF.sub.3,
--CH.sub.2CCl.sub.3, perfluoroalkyl (e.g., --CF.sub.3), and the
like.
[0064] "Haloalkoxy" means a moiety of the formula --OR, wherein R
is a haloalkyl moiety as defined herein. Examples of alkoxy
moieties include, but are not limited to, methoxy, ethoxy,
isopropoxy, and the like.
[0065] "Hydroxyalkyl" refers to a subset of heteroalkyl and refers
in particular to an alkyl moiety as defined herein that is
substituted with one or more, preferably one, two or three hydroxy
groups, provided that the same carbon atom does not carry more than
one hydroxy group. Representative examples include, but are not
limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl,
3-hydroxypropyl, 1-(hydroxymethyl)-2-met- hylpropyl,
2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl,
2,3-dihydroxypropyl, 2-hydroxy-1-hydroxymethylethyl,
2,3-dihydroxybutyl, 3,4-dihydroxybutyl and
2-(hydroxymethyl)-3-hydroxypropyl
[0066] "Heterocycloamino" means a saturated ring wherein at least
one ring atom is N, NH or N-alkyl and the remaining ring atoms form
an alkylene group.
[0067] "Heterocyclyl" means a monovalent saturated moiety,
consisting of one to three rings, incorporating one, two, or three
or four heteroatoms (chosen from nitrogen, oxygen or sulfur). The
heterocyclyl ring may be optionally substituted as defined herein.
Examples of heterocyclyl moieties include, but are not limited to,
optionally substituted piperidinyl, piperazinyl, homopiperazinyl,
azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl,
imidazolidinyl, pyridinyl, pyridazinyl, pyrimidinyl, oxazolidinyl,
isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl,
quinuclidinyl, quinolinyl, isoquinolinyl, benzimidazolyl,
thiadiazolylidinyl, benzothiazolidinyl, benzoazolylidinyl,
dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl,
thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone,
dihydroquinolinyl, dihydrisoquinolinyl, tetrahydroquinolinyl,
tetrahydrisoquinolinyl, and the like.
[0068] "Heterocyclylalkyl" means a group --R--R' wherein R' is
heterocyclyl as defined herein and R is alkylene.
[0069] "Imidazolinyl" as used herein means a group of the formula:
8
[0070] wherein R' is hydrogen or alkyl. Imidazolinyl groups may be
optionally substituted as defined herein.
[0071] "Imidazolinylalkyl" means a group --R--R' wherein R' is
imidazolinyl as defined herein and R is alkylene.
[0072] "Imidazolinylaminoalkyl" means a group --R--R'--R" wherein
R" is imidazolinyl as defined herein, R' is amino, and R is
alkylene. The amino moiety of "imidazolinylaminoalkyl" may be
optionally substituted with alkyl.
[0073] "Pyrimidinylaminoalkyl" means a group --R--R'--R" wherein R"
is pyrinmidinyl (preferably pyrimidin-2-yl), R' is amino, and R is
alkylene. The pyrimidinyl moiety of "pyrimidinylaminoalkyl" may be
optionally substituted as defined herein, and the amino moiety of
"pyrimidinylaminoalkyl" may be optionally substituted with
alkyl.
[0074] "Tetrahydropyrimidinyl" means 1,4,5,6-tetrahydropyrimidinyl,
preferably 1,4,5,6-tetrahydropyrimidin-2-yl, and may be optionally
substituted as defined herein. "Tetrahydropyrimidinyl" includes
5,5-dimethyl-1,4,5,6-tetrahydropyrimidin-2-yl.
[0075] "Tetrahydropyrimidinylaminoalkyl" means a group --R--R'--R"
wherein R" is tetrahydropyrimidinyl, R' is amino, and R is
alkylene. The amino moiety of "tetrahydropyrimidinylaminoalkyl" may
be optionally substituted with alkyl.
[0076] "Urea" means a group of the formula: 9
[0077] wherein R.sup.g, R.sup.h and R.sup.i each independently is
hydrogen or alkyl.
[0078] "Urealkyl" means a group R--R' wherein R' is urea and R is
alkylene.
[0079] "Optionally substituted", when used in association with
"aryl", phenyl", "heteroaryl" or "heterocyclyl", means an aryl,
phenyl, heteroaryl or heterocyclyl which is optionally substituted
independently with one to four substituents, preferably one or two
substituents selected from alkyl, cycloalkyl, cycloalkylalkyl,
heteroalkyl, hydroxyalkyl, halo, nitro, cyano, hydroxy, alkoxy,
amino, acylamino, mono-alkylamino, di-alkylamino, haloalkyl,
haloalkoxy, heteroalkyl, --COR (where R is hydrogen, alkyl, phenyl
or phenylalkyl), --(CR'R").sub.n--COOR (where n is an integer from
0 to 5, R' and R" are independently hydrogen or alkyl, and R is
hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or
phenylalkyl), or --CR'R").sub.n--CONR.sup.aR.s- up.b (where n is an
integer from 0 to 5, R' and R" are independently hydrogen or alkyl,
and R.sup.a and R.sup.b are, independently of each other, hydrogen,
alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl).
[0080] "Leaving group" means the group with the meaning
conventionally associated with it in synthetic organic chemistry,
i.e., an atom or group displaceable under substitution reaction
conditions. Examples of leaving groups include, but are not limited
to, halogen, alkane- or arylenesulfonyloxy, such as
methanesulfonyloxy, ethanesulfonyloxy, thiomethyl,
benzenesulfonyloxy, tosyloxy, and thienyloxy, dihalophosphinoyloxy,
optionally substituted benzyloxy, isopropyloxy, acyloxy, and the
like.
[0081] "Modulator" means a molecule that interacts with a target.
The interactions include, but are not limited to, agonist,
antagonist, and the like, as defmed herein.
[0082] "Optional" or "optionally" means that the subsequently
described event or circumstance may but need not occur, and that
the description includes instances where the event or circumstance
occurs and instances in which it does not.
[0083] "Disease" and "Disease state" means any disease, condition,
symptom, disorder or indication.
[0084] "Inert organic solvent" or "inert solvent" means the solvent
is inert under the conditions of the reaction being described in
conjunction therewith, including for example, benzene, toluene,
acetonitrile, tetrahydrofuran, N,N-dimethylformamide, chloroform,
methylene chloride or dichloromethane, dichloroethane, diethyl
ether, ethyl acetate, acetone, methyl ethyl ketone, methanol,
ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine,
and the like. Unless specified to the contrary, the solvents used
in the reactions of the present invention are inert solvents.
[0085] "Pharmaceutically acceptable" means that which is useful in
preparing a pharmaceutical composition that is generally safe,
non-toxic, and neither biologically nor otherwise undesirable and
includes that which is acceptable for veterinary as well as human
pharmaceutical use.
[0086] "Pharmaceutically acceptable salts" of a compound means
salts that are pharmaceutically acceptable, as defined herein, and
that possess the desired pharmacological activity of the parent
compound. Such salts include: acid addition salts formed with
inorganic acids such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid, and the like; or
formed with organic acids such as acetic acid, benzenesulfonic
acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic
acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic
acid, glycolic acid, hydroxynaphtoic acid, 2-hydroxyethanesulfonic
acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic
acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic
acid, propionic acid, salicylic acid, succinic acid, tartaric acid,
p-toluenesulfonic acid, trimethylacetic acid, and the like; or
salts formed when an acidic proton present in the parent compound
either is replaced by a metal ion, e.g., an alkali metal ion, an
alkaline earth ion, or an aluminum ion; or coordinates with an
organic or inorganic base. Acceptable organic bases include
diethanolamine, ethanolamine, N-methylglucamine, triethanolamine,
tromethamine, and the like. Acceptable inorganic bases include
aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium
carbonate and sodium hydroxide.
[0087] The preferred pharmaceutically acceptable salts are the
salts formed from acetic acid, hydrochloric acid, sulphuric acid,
methanesulfonic acid, maleic acid, phosphoric acid, tartaric acid,
citric acid, sodium, potassium, calcium, zinc, and magnesium.
[0088] It should be understood that all references to
pharmaceutically acceptable salts include solvent addition forms
(solvates) or crystal forms (polymorphs) as defined herein, of the
same acid addition salt.
[0089] The terms "pro-drug" and "prodrug", which may be used
interchangeably herein, refer to any compound which releases an
active parent drug according to formula I in vivo when such prodrug
is administered to a mammalian subject. Prodrugs of a compound of
formula I are prepared by modifying one or more functional group(s)
present in the compound of formula I in such a way that the
modification(s) may be cleaved in vivo to release the parent
compound. Prodrugs include compounds of formula I wherein a
hydroxy, amino, or sulfhydryl group in a compound of Formula I is
bonded to any group that may be cleaved in vivo to regenerate the
free hydroxyl, amino, or sulfhydryl group, respectively. Examples
of prodrugs include, but are not limited to, esters (e.g., acetate,
formate, and benzoate derivatives), carbamates (e.g.,
N,N-dimethylaminocarbonyl) of hydroxy functional groups in
compounds of formula I, N-acyl derivatives (e.g. N-acetyl)
N-Mannich bases, Schiff bases and enaminones of amino functional
groups, oximes, acetals, ketals and enol esters of ketone and
aldehyde functional groups in compounds of Formula I, and the like,
see Bundegaard, H. "Design of Prodrugs" p1-92, Elsevier, New
York-Oxford (1985), and the like.
[0090] "Protective group" or "protecting group" means the group
which selectively blocks one reactive site in a multifunctional
compound such that a chemical reaction can be carried out
selectively at another unprotected reactive site in the meaning
conventionally associated with it in synthetic chemistry. Certain
processes of this invention rely upon the protective groups to
block reactive nitrogen and/or oxygen atoms present in the
reactants. For example, the terms "amino-protecting group" and
"nitrogen protecting group" are used interchangeably herein and
refer to those organic groups intended to protect the nitrogen atom
against undesirable reactions during synthetic procedures.
Exemplary nitrogen protecting groups include, but are not limited
to, trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl
(carbobenzyloxy, CBZ), p-methoxybenzyloxycarbonyl,
p-nitrobenzyloxycarbonyl, tert-butoxycarbonyl (BOC), and the like.
Persons skilled in the art will know how to choose a group for the
ease of removal and for the ability to withstand the following
reactions.
[0091] "Solvates" means solvent additions forms that contain either
stoichiometric or non stoichiometric amounts of solvent. Some
compounds have a tendency to trap a fixed molar ratio of solvent
molecules in the crystalline solid state, thus forming a solvate.
If the solvent is water the solvate formed is a hydrate, when the
solvent is alcohol, the solvate formed is an alcoholate. Hydrates
are formed by the combination of one or more molecules of water
with one of the substances in which the water retains its molecular
state as H.sub.2O, such combination being able to form one or more
hydrate.
[0092] "Subject" means mammals and non-mammals. Mammals means any
member of the mammalia class including, but not limited to, humans;
non-human primates such as chimpanzees and other apes and monkey
species; farm animals such as cattle, horses, sheep, goats, and
swine; domestic animals such as rabbits, dogs, and cats; laboratory
animals including rodents, such as rats, mice, and guinea pigs; and
the like. Examples of non-mammals include, but are not limited to,
birds, and the like. The term "subject" does not denote a
particular age or sex.
[0093] "Treating" or "treatment" of a disease state includes:
[0094] (i) preventing the disease state, i.e. causing the clinical
symptoms of the disease state not to develop in a subject that may
be exposed to or predisposed to the disease state, but does not yet
experience or display symptoms of the disease state.
[0095] (ii) inhibiting the disease state, i.e., arresting the
development of the disease state or its clinical symptoms, or
[0096] (iii) relieving the disease state, i.e., causing temporary
or permanent regression of the disease state or its clinical
symptoms.
[0097] The terms "treating", "contacting" and "reacting" when
referring to a chemical reaction means adding or mixing two or more
reagents under appropriate conditions to produce the indicated
and/or the desired product. It should be appreciated that the
reaction which produces the indicated and/or the desired product
may not necessarily result directly from the combination of two
reagents which were initially added, i.e., there may be one or more
intermediates which are produced in the mixture which ultimately
leads to the formation of the indicated and/or the desired
product.
[0098] Nomenclature and Structures
[0099] In general, the nomenclature used in this Application is
based on AUTONOM.TM. v.4.0, a Beilstein Institute computerized
system for the generation of IUPAC systematic nomenclature.
Chemical structures shown herein were prepared using ISIS.RTM.
version 2.2. Any open valency appearing on a carbon, oxygen or
nitrogen atom in the structures herein indicates the presence of a
hydrogen atom. Numbering of ring positions of the benzodioxane,
benzoxazine and benzothiazine compounds of the invention is done
according to the formula: 10
[0100] Compounds
[0101] The invention provides compounds of the formula I: 11
[0102] or a pharmaceutically acceptable salt thereof, wherein:
[0103] m is from 0 to 3;
[0104] n is from 1 to 3;
[0105] p is from 0 to 3;
[0106] Ar is optionally substituted aryl or optionally substituted
heteroaryl;
[0107] X is --O--, --S-- or --NR-- wherein R.sup.a is hydrogen,
C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl or
C.sub.1-6alkylsulfonyl;
[0108] R.sup.1 and R.sup.2 each independently is hydrogen,
C.sub.1-6alkyl, C.sub.1-6alkoxy-C.sub.1-6alkyl, or
hydroxy-C.sub.1-6alkyl;
[0109] or one of R.sup.1 and R.sup.2 is hydrogen or C.sub.1-6alkyl
and the other is C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl,
aryl-C.sub.1-6alkyl, hydroxy, or a five- or six-membered heteroaryl
or heterocyclyl that contains one or two nitrogens;
[0110] or R.sup.1 and R.sup.2 together with the nitrogen to which
they are attached may form a three- to seven-membered ring that
optionally contains an additional heteroatom selected from N, O and
S;
[0111] or R.sup.1 and R.sup.2 together with the nitrogen to which
they are attached may form a guanidinyl group, an amidinyl group, a
carbamyl group, or a urea group;
[0112] each R.sup.3 is independently C.sub.1-6alkyl,
hydroxy-C.sub.1-6alkyl or C.sub.1-6alkoxy-C.sub.1-6alkyl;
[0113] or two of R.sup.3 together with the atoms to which they are
attached may form a C.sub.4-6carbocyclic ring;
[0114] or one of R.sup.3 together with one of R.sup.1 and R.sup.2
and the atoms to which they are attached may form a five or
six-membered ring;
[0115] R.sup.4 and R.sup.5 each independently is hydrogen or
C.sub.1-6alkyl;
[0116] or one of R.sup.4 and R.sup.5 together with one of R.sup.1
and R.sup.2 and the atoms to which they are attached may form a
five or six-membered ring;
[0117] or R.sup.4 and R.sup.5 together may form .dbd.NR.sup.f
wherein R.sup.f is hydrogen or C.sub.1-6alkyl; and
[0118] each R.sup.6 is independently halo, C.sub.1-6alkyl,
halo-C.sub.1-6alkyl, hetero-C.sub.1-6alkyl, cyano,
--SO.sub.2R.sup.b, --C(.dbd.O)--NR.sup.cR.sup.d, --SR.sup.c,
--C(.dbd.O)--R.sup.c, where each of R.sup.b, R.sup.c and R.sup.d is
independently hydrogen or C.sub.1-6alkyl.
[0119] It is to be understood that the scope of this invention
encompasses not only the various isomers which may exist but also
the various mixture of isomers which may be formed. Furthermore,
the scope of the invention also encompasses solvates, salts and
prodrugs of the subject compounds.
[0120] In many embodiments of formula I, X is --O--.
[0121] In certain embodiments of the invention, the subject
compounds are of the formula II: 12
[0122] wherein m, n, p, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5
and R.sup.6 are as defined herein.
[0123] In certain embodiments of formula I or formula II, R.sup.4
and R.sup.5 are hydrogen.
[0124] In certain embodiments of formula I or formula II, m is
0.
[0125] In certain embodiments of formula I or formula II, n is 1 or
2. Preferably n is 1.
[0126] In certain embodiments of formula I or formula II, p is
0.
[0127] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 each independently is hydrogen or C.sub.1-6alkyl, or
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a three, four, five or six-membered ring.
[0128] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 each independently is hydrogen or C.sub.1-6alkyl.
[0129] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three, four, five or six-membered ring.
[0130] In certain embodiments of formula I or formula II, Ar is
optionally substituted phenyl.
[0131] In certain embodiments of formula I or formula II, R.sup.4
and R.sup.5 together form .dbd.NR.sup.f wherein R.sup.f is hydrogen
or C.sub.1-6alkyl.
[0132] In certain embodiments of formula I or formula II, one of
R.sup.1 and R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
hydroxy, or a five- or six-membered heteroaryl or heterocyclyl that
contains one or two nitrogens.
[0133] In certain embodiments of formula I or formula II, one of
R.sup.4 and R.sup.5 together with one of R.sup.1 and R.sup.2 and
the atoms to which they are attached form a five or six-membered
ring.
[0134] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a guanidinyl group, an amidinyl group, a carbamyl group, or a
urea group. Preferably in such embodiments, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
guanidinyl group.
[0135] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three- to seven-membered ring that optionally contains an
additional heteroatom selected from N, O and S.
[0136] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three-membered ring.
[0137] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a four-membered ring.
[0138] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a five-membered ring.
[0139] In certain embodiments of formula I or formula II, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a six-membered ring.
[0140] In certain embodiments of formula I or formula II, m is 1
and R.sup.3 is alkyl.
[0141] In certain embodiments of formula I or formula II, m is 1
and one of R.sup.1 and R.sup.2 together with R.sup.3 and the atoms
to which they are attached form a five or six membered ring.
[0142] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, and R.sup.4 and R.sup.5 are hydrogen.
[0143] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, and Ar is
optionally substituted phenyl.
[0144] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, and R.sup.1 and R.sup.2 each independently is
hydrogen or C.sub.1-6alkyl.
[0145] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, and R.sup.1 and R.sup.2 together with the
nitrogen to which they are attached form a three- to seven-membered
ring that optionally contains an additional heteroatom selected
from N, O and S.
[0146] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, and R.sup.1 and R.sup.2 together with the
nitrogen to which they are attached form a guanidinyl group, an
amidinyl group, or a urea group. In such embodiments, R.sup.1 and
R.sup.2 together with the nitrogen to which they are attached
preferably form a guanidinyl group.
[0147] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, one of R.sup.1 and R.sup.2 is hydrogen or
C.sub.1-6alkyl and the other is C.sub.1-6alkylcarbonyl,
C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl, or a five- or
six-membered heteroaryl or heterocyclyl that contains one or two
nitrogens. Preferred heteroaryl include imidazolyl, pyrazolyl,
pyridyl and pyrimidyl. Preferred heterocyclyl include imidazolinyl
and tetrahydropyrimidinyl.
[0148] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, one of R.sup.1 and R.sup.2 is hydrogen or
C.sub.1-6alkyl and the other is C.sub.1-6alkylcarbonyl. Preferably
in such embodiments, R.sup.1 is hydrogen and R.sup.2 is acetyl.
[0149] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, one of R.sup.1 and R.sup.2 is hydrogen or
C.sub.1-6alkyl and the other is C.sub.3-8cycloalkyl.
[0150] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, one of R.sup.1 and R.sup.2 is hydrogen or
C.sub.1-6alkyl and the other is aryl-C.sub.1-6alkyl. Preferably in
such embodiments, R.sup.1 is hydrogen and R.sup.2 is benzyl.
[0151] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, Ar is optionally
substituted phenyl, one of R.sup.1 and R.sup.2 is C.sub.1-6alkyl,
and the other is hydroxy.
[0152] In certain embodiments of the invention, the subject
compounds are of the formula III: 13
[0153] wherein:
[0154] n is 1 or2;
[0155] q is from 0 to 4;
[0156] each R.sup.7is independently halo, C.sub.1-6alkyl,
halo-C.sub.1-6alkyl, hetero-C.sub.1-6alkyl, cyano,
--SO.sub.2R.sup.b, --C(.dbd.O)--NR.sup.cR.sup.d, --SR.sup.c,
--C(.dbd.O)--R.sup.c, where each of R.sup.b, R.sup.c and R.sup.d is
independently hydrogen or C.sub.1-6alkyl; and
[0157] m, p, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and
R.sup.6 are as defined herein.
[0158] In certain embodiments of formula III, R.sup.4 and R.sup.5
are hydrogen.
[0159] In certain embodiments of formula III, m is 0.
[0160] In certain embodiments of formula III, n is 1 or 2.
Preferably n is 1.
[0161] In certain embodiments of formula III, p is 0.
[0162] In certain embodiments of formula III, R.sup.1 and R.sup.2
each independently is hydrogen or C.sub.1-6alkyl, or R.sup.1 and
R.sup.2 together with the nitrogen to which they are attached form
a three, four, five or six-membered ring.
[0163] In certain embodiments of formula III, R.sup.1 and R.sup.2
each independently is hydrogen or C.sub.1-6alkyl.
[0164] In certain embodiments of formula III, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a three,
four, five or six-membered ring.
[0165] In certain embodiments of formula II, R.sup.4 and R.sup.5
together form .dbd.NR.sup.f wherein R.sup.f is hydrogen or
C.sub.1-6alkyl.
[0166] In certain embodiments of formula III, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
hydroxy, or a five- or six-membered heteroaryl or heterocyclyl that
contains one or two nitrogens.
[0167] In certain embodiments of formula III, one of R.sup.4 and
R.sup.5 together with one of R.sup.1 and R.sup.2 and the atoms to
which they are attached form a five or six-membered ring.
[0168] In certain embodiments of formula III, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
guanidinyl group, an amidinyl group, a carbamyl group, or a urea
group. Preferably in such embodiments, R.sup.1 and R.sup.2 together
with the nitrogen to which they are attached form a guanidinyl
group.
[0169] In certain embodiments of formula III, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a three-
to seven-membered ring that optionally contains an additional
heteroatom selected from N, O and S.
[0170] In certain embodiments of formula III, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
three-membered ring.
[0171] In certain embodiments of formula III, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
four-membered ring.
[0172] In certain embodiments of formula III, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
five-membered ring.
[0173] In certain embodiments of formula III, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
six-membered ring.
[0174] In certain embodiments of formula III, m is 1 and R.sup.3 is
alkyl.
[0175] In certain embodiments of formula III, m is 1 and one of
R.sup.1 and R.sup.2 together with R.sup.3 and the atoms to which
they are attached form a five or six membered ring.
[0176] In certain embodiments of formula III, n is 1, m is 0, p is
0, and R.sup.4 and R.sup.5 are hydrogen.
[0177] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, and R.sup.7
is C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy
[0178] In certain embodiments of formula I or formula II, n is 1, m
is 0, p is 0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2,
R.sup.7is C.sub.16alkyl, halo, halo-C.sub.1-6alkyl,
C.sub.1-6alkoxy, or cyano, and R.sup.1 and R.sup.2 each
independently is hydrogen or C.sub.1-6alkyl.
[0179] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, R.sup.7 is
C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or
cyano, and R.sup.1 and R.sup.2 together with the nitrogen to which
they are attached form a three- to seven-membered ring that
optionally contains an additional heteroatom selected from N, O and
S.
[0180] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, R.sup.7is
C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or
cyano, and R.sup.1 and R.sup.2 together with the nitrogen to which
they are attached form a guanidinyl group, an amidinyl group, or a
urea group. In such embodiments, R.sup.1 and R.sup.2 together with
the nitrogen to which they are attached preferably form a
guanidinyl group.
[0181] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, R.sup.7is
C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or
cyano, one of R.sup.1 and R.sup.2 is hydrogen or C.sub.1-6alkyl and
the other is C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl,
aryl-C.sub.1-6alkyl, or a five- or six-membered heteroaryl or
heterocyclyl that contains one or two nitrogens. Preferred
heteroaryl include imidazolyl, pyrazolyl, pyridyl and pyrimidyl.
Preferred heterocyclyl include imidazolinyl, and
tetrahydropyrimidinyl.
[0182] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, R.sup.7is
C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or
cyano and R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl. Preferably in such embodiments, R.sup.1 is
hydrogen and R.sup.2 is acetyl.
[0183] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, R.sup.7is
C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyan
and R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.3-8cycloalkyl.
[0184] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, R.sup.7is
C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyan
and R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
aryl-C.sub.1-6alkyl. Preferably in such embodiments, R.sup.1 is
hydrogen and R.sup.2 is benzyl.
[0185] In certain embodiments of formula III, n is 1, m is 0, p is
0, R.sup.4 and R.sup.5 are hydrogen, q is from 0 to 2, R.sup.7 is
C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or
cyano, one of R.sup.1 and R.sup.2 is C.sub.1-6alkyl, and the other
is hydroxy.
[0186] Compounds of formula III may, in certain embodiments, be
more specifically of formula IV: 14
[0187] wherein n, p, q, R.sup.1, R.sup.2, R.sup.3, R.sup.6 and
R.sup.7 are as defined herein.
[0188] Compounds of formula III may, in certain embodiments, be
more specifically of formula V; 15
[0189] wherein n, p, q, R.sup.1, R.sup.2, R.sup.3, R.sup.6 and
R.sup.7 are as defined herein.
[0190] In certain embodiments of formula IV or formula V, n is 1 or
2. Preferably n is 1.
[0191] In certain embodiments of formula IV or formula V, p is
0.
[0192] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 each independently is hydrogen or C.sub.1-6alkyl, or
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a three, four, five or six-membered ring.
[0193] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 each independently is hydrogen or C.sub.1-6alkyl.
[0194] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three, four, five or six-membered ring.
[0195] In certain embodiments of formula IV or formula V, one of
R.sup.1 and R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
hydroxy, or a five- or six-membered heteroaryl or heterocyclyl that
contains one or two nitrogens.
[0196] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a guanidinyl group, an amidinyl group, a carbamyl group, or a
urea group. Preferably in such embodiments, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
guanidinyl group.
[0197] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three- to seven-membered ring that optionally contains an
additional heteroatom selected from N, O and S.
[0198] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three-membered ring.
[0199] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a four-membered ring.
[0200] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a five-membered ring.
[0201] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a six-membered ring.
[0202] In certain embodiments of formula IV or formula V, n is 1
and p is 0.
[0203] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, and R.sup.7 is C .sub.16alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano.
[0204] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, and R.sup.1 and
R.sup.2 each independently is hydrogen or C.sub.1-6alkyl.
[0205] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, and R.sup.1 and
R.sup.2 together with the nitrogen to which they are attached form
a three- to seven-membered ring that optionally contains an
additional heteroatom selected from N, O and S.
[0206] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, and R.sup.1 and
R.sup.2 together with nitrogen to which they are attached form a
guanidinyl group, an amidinyl group, or a urea group. In such
embodiments, R.sup.1 and R.sup.2 together with the nitrogen to
which they are attached preferably form a guanidinyl group.
[0207] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
or a five- or six-membered heteroaryl or heterocyclyl that contains
one or two nitrogens. Preferred heteroaryl include imidazolyl,
pyrazolyl, pyridyl and pyrimidyl. Preferred heterocyclyl include
imidazolinyl, and tetrahydropyrimidinyl.
[0208] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl. Preferably in such embodiments, R.sup.1 is
hydrogen and R.sup.2 is acetyl.
[0209] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.3-8cycloalkyl.
[0210] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
aryl-C.sub.1-6alkyl. Preferably in such embodiments, R.sup.1 is
hydrogen and R.sup.2 is benzyl.
[0211] In certain embodiments of formula IV or formula V, n is 1, p
is 0, q is from 0 to 2, R.sup.7is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is C.sub.1-6alkyl, and the other is hydroxy.
[0212] In certain embodiments of formula IV, one of R.sup.3is
C.sub.1-6alkyl and the other is hydrogen.
[0213] In certain embodiments of formula IV, both of R.sup.3 are
hydrogen.
[0214] In certain embodiments of formula IV, both of R.sup.3 are
C.sub.1-6alkyl.
[0215] In certain embodiments of formula IV, both of R.sup.3
together with the atoms to which they are attached form a
C.sub.4-6carbocyclic ring.
[0216] In certain embodiments of formula V, R.sup.3is
C.sub.1-6alkyl.
[0217] In certain embodiments of formula V, R.sup.3is hydrogen.
[0218] In certain embodiments of formula V, R.sup.3 together with
one of R.sup.1 and R.sup.2 and the atoms to which they are attached
form a five- or six-membered ring. Preferably in such embodiments
R.sup.3 together with one of R.sup.1 and R.sup.2 and the atoms to
which they are attached form a five-membered ring.
[0219] The subject compounds may, in certain embodiments, be of the
formula VI: 16
[0220] wherein n, q, R.sup.1, R.sup.2 and R.sup.7 are as defined
herein.
[0221] The subject compounds may, in certain embodiments, be of the
formula VII: 17
[0222] wherein n, q, R.sup.1, R.sup.2 and R.sup.7 are as defined
herein.
[0223] In certain embodiments of formula VI or formula VII, n is 1
or 2. Preferably n is 1.
[0224] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 each independently is hydrogen or C.sub.1-6alkyl, or
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a three, four, five or six-membered ring.
[0225] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 each independently is hydrogen or C.sub.1-6alkyl.
[0226] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three, four, five or six-membered ring.
[0227] In certain embodiments of formula VI or formula VII, one of
R.sup.1 and R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
hydroxy, or a five- or six-membered heteroaryl or heterocyclyl that
contains one or two nitrogens.
[0228] In certain embodiments of formula IV or formula V, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a guanidinyl group, an amidinyl group, a carbamyl group, or a
urea group. Preferably in such embodiments, R.sup.1 and R.sup.2
together with the nitrogen to which they are attached form a
guanidinyl group.
[0229] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three- to seven-membered ring that optionally contains an
additional heteroatom selected from N, O and S.
[0230] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a three-membered ring.
[0231] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a four-membered ring.
[0232] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a five-membered ring.
[0233] In certain embodiments of formula VI or formula VII, R.sup.1
and R.sup.2 together with the nitrogen to which they are attached
form a six-membered ring.
[0234] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, and R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano.
[0235] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, and R.sup.1 and
R.sup.2 each independently is hydrogen or C.sub.1-6alkyl.
[0236] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, and R.sup.1 and
R.sup.2 together with the nitrogen to which they are attached form
a three- to seven-membered ring that optionally contains an
additional heteroatom selected from N, O and S.
[0237] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, and R.sup.1 and
R.sup.2 together with the nitrogen to which they are attached form
a guanidinyl group, an amidinyl group, or a urea group. In such
embodiments, R.sup.1 and R.sup.2 together with the nitrogen to
which they are attached preferably form a guanidinyl group.
[0238] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
or a five- or six-membered heteroaryl or heterocyclyl that contains
one or two nitrogens. Preferred heteroaryl include imidazolyl,
pyrazolyl, pyridyl and pyrimidyl. Preferred heterocyclyl include
imidazolinyl, and tetrahydropyrimidinyl.
[0239] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl. Preferably in such embodiments, R.sup.1 is
hydrogen and R.sup.2 is acetyl.
[0240] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6 alkyl and the other is
C.sub.3-8cycloalkyl.
[0241] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6 alkyl and the other is
aryl-C.sub.1-6alkyl. Preferably in such embodiments, R.sup.1 is
hydrogen and R.sup.2 is benzyl.
[0242] In certain embodiments of formula VI or formula VII, n is 1,
q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is C.sub.1-6alkyl, and the other is hydroxy.
[0243] The subject compounds may, in certain embodiments, be of the
formula VIII: 18
[0244] wherein q, R.sup.1, R.sup.2 and R.sup.7 are as defined
herein.
[0245] The subject compounds may, in certain embodiments, be of the
formula IX: 19
[0246] wherein q, R.sup.1, R.sup.2 and R.sup.7 are as defined
herein.
[0247] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 each independently is hydrogen or
C.sub.1-6alkyl, or R.sup.1 and R.sup.2 together with the nitrogen
to which they are attached form a three, four, five or six-membered
ring.
[0248] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 each independently is hydrogen or
C.sub.1-6alkyl.
[0249] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a three, four, five or six-membered ring.
[0250] In certain embodiments of formula VIII or formula IX, one of
R.sup.1 and R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
hydroxy, or a five- or six-membered heteroaryl or heterocyclyl that
contains one or two nitrogens.
[0251] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a guanidinyl group, an amidinyl group, a carbamyl
group, or a urea group. Preferably in such embodiments, R.sup.1 and
R.sup.2 together with the nitrogen to which they are attached form
a guanidinyl group.
[0252] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a three- to seven-membered ring that optionally
contains an additional heteroatom selected from N, O and S.
[0253] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a three-membered ring.
[0254] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a four-membered ring.
[0255] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a five-membered ring.
[0256] In certain embodiments of formula VIII or formula IX,
R.sup.1 and R.sup.2 together with the nitrogen to which they are
attached form a six-membered ring.
[0257] In certain embodiments of formula VIII or formula IX, q is
from 0 to 2, and R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano.
[0258] In certain embodiments of formula VIII or formula IX, q is
from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl,
C.sub.1-6alkoxy, or cyano, and R.sup.1 and R.sup.2 each
independently is hydrogen or C.sub.1-6alkyl.
[0259] In certain embodiments of formula VIII or formula IX, q is
from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl,
C.sub.1-6alkoxy, or cyano, and R.sup.1 and R.sup.2 together with
the nitrogen to which they are attached form a three- to
seven-membered ring that optionally contains an additional
heteroatom selected from N, O and S.
[0260] In certain embodiments of formula VIII or formula IX, q is
from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl,
C.sub.1-6alkoxy, or cyano, and R.sup.1 and R.sup.2 together with
the nitrogen to which they are attached form a guanidinyl group, an
amidinyl group, or a urea group. In such embodiments, R.sup.1 and
R.sup.2 together with the nitrogen to which they are attached
preferably form a guanidinyl group.
[0261] In certain embodiments of formula VIII or formula IX, p is
0, q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.1-6alkylcarbonyl, C.sub.3-8cycloalkyl, aryl-C.sub.1-6alkyl,
or a five- or six-membered heteroaryl or heterocyclyl that contains
one or two nitrogens. Preferred heteroaryl include imidazolyl,
pyrazolyl, pyridyl and pyrimidyl. Preferred heterocyclyl include
imidazolinyl, and tetrahydropyrimidinyl.
[0262] In certain embodiments of formula VIII or formula IX, q is
from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl,
C.sub.1-6alkoxy, or cyano, one of R.sup.1 and R.sup.2 is hydrogen
or C.sub.1-6alkyl and the other is C.sub.1-6alkylcarbonyl.
Preferably in such embodiments, R.sup.1 is hydrogen and R.sup.2 is
acetyl.
[0263] In certain embodiments of formula VIII or formula IX, n is
1, p is 0, q is from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo,
halo-C.sub.1-6alkyl, C.sub.1-6alkoxy, or cyano, one of R.sup.1 and
R.sup.2 is hydrogen or C.sub.1-6alkyl and the other is
C.sub.3-8cycloalkyl.
[0264] In certain embodiments of formula VIII or formula IX, q is
from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl,
C.sub.1-6alkoxy, or cyano, one of R.sup.1 and R.sup.2 is hydrogen
or C.sub.1-6alkyl and the other is aryl-C.sub.1-6alkyl. Preferably
in such embodiments, R.sup.1 is hydrogen and R.sup.2 is benzyl.
[0265] In certain embodiments of formula VIII or formula IX, q is
from 0 to 2, R.sup.7 is C.sub.1-6alkyl, halo, halo-C.sub.1-6alkyl,
C.sub.1-6alkoxy, or cyano, one of R.sup.1 and R.sup.2 is
C.sub.1-6alkyl, and the other is hydroxy.
[0266] In certain embodiments of formula VIII, q is 0 or 1, R.sup.7
is halo, one of R.sup.1 and R.sup.2 is C.sub.1-6alkyl, and the
other is hydrogen.
[0267] Where any of R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6 or R.sup.7 are alkyl or contain an alkyl moiety, such alkyl
is preferably lower alkyl, i.e. C.sub.1-C.sub.6alkyl, and more
preferably C.sub.1-C.sub.4alkyl.
[0268] Representative compounds in accordance with the methods of
the invention are shown in Table 1. Melting points shown in Table 1
represent the corresponding hydrochloride salts unless indicated
otherwise.
1TABLE 1 # Structure Name (Autonom .TM.) Mp .degree. C. 1 20
(+-)-(7-Benzenesulfonyl-2,3- dihydro-benzo[1,4]dioxin-2-
ylmethyl)-methyl-amine 198.0-199.4 2 21
(7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2--(S)-
ylmethyl)-methyl-amine 240.0-243.6 3 22
(7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-(R)-
ylmethyl)-methyl-amine 247.1-249.9 4 23
(6-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-(R)-
ylmethyl)-methyl-amine 219.7-225.4 5 24
(6-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-(S)-
ylmethyl)-methyl-amine 218.2-220.5 6 25
(7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-yl)- methylamine
107.8-111.9 7 26 [7-(3-Fluoro-benzenesulfonyl)-
2,3-dihydro-benzo[1,4]dioxin-2- (S)-ylmethyl]-methyl-amine
245.8-246.4 8 27 [7-(3-Fluoro-benzenesulfonyl)-
2,3-dihydro-benzo[1,4]di- oxin-2- (R)-ylmethyl]-methyl-amine
250.1-254.3 9 28 C-[7-(3-Fluoro-benzenesulfonyl)-
2,3-dihydro-benzo[1,4]dioxin-2- (S)-yl]-methylamine 224.9-227.9 10
29 1-(7-Benzenesulfonyl-2,3- dihydro-benzol[1,4]dioxin-2-(R)-
ylmethyl)-pyrrolidine 75.8-112.7 11 30 Benzyl-[7-(3-fluoro-
benzenesulfonyl)-2,3-dihydro- benzo[1,4]dioxin-2-ylmethyl]- amine
195.1-197.1 12 31 Methyl-[7-(toluene-4-sulfonyl)-
2,3-dihydro-benzo[1,4]dioxin-2- ylmethyl]-amine 213.0-214.1 13 32
Ethyl-[7-(3-fluoro- benzenesulfonyl)-2,3-dihydro-
benzo[1,4]dioxin-2-ylmethyl]- amine 247.5-251.3 14 33
[7-(3-Fluoro-benzenesulfonyl)- 2,3-dihydro-benzo[1,4]dioxin-2-
ylmethyl]-dimethyl-amine 228.7-231.3 15 34
[7-(3-Fluoro-benzenesulfonyl)- 2,3-dihydro-benzo[1,4]dio- xin-2-
ylmethyl]-isopropyl-amine 242.4-243.8 16 35
1-[7-(3-Fluoro-benzenesulfonyl)- 2,3-dihydro-benzo[1,4]dioxin-2-
ylmethyl]-azetidine 100.8-108.3 17 36
[7-(3-Fluoro-benzenesulfonyl)- 2,3-dihydro-benzo[1,4]dioxin-2-
ylmethyl]-(2-methoxy-ethyl)- amine 193.0-196.9 18 37
4-[7-(3-Fluoro-benzenesulfonyl)- 2,3-dihydro-benzo[1,4]dioxin-2-
ylmethyl]-morpholine 19 38 1-(7-Benzenesulfonyl-2,3-
dihydro-benzo[1,4]dioxin-2- ylmethyl)-azetidine 132.3 135.5 20 39
1-[7-(3-Fluoro-benzenesulfonyl)- 2,3-dihydro-benzo[1,4]dioxin-2-
ylmethyl]-aziridine 215.4-217.2 21 40
(7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-ylmethyl)-
benzyl-amine 220.9-224.9 22 41 C-(7-Benzenesulfonyl-2,3-
dihydro-benzo[1,4]dioxin-2-yl)- methylamine 23 42
(7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-ylmethyl)-
dimethyl-amine 232.0-233.5 24 43 (7-Benzenesulfonyl-2,3-d- ihydro-
benzo[1,4]dioxin-2-ylmethyl)- isopropyl-amine 224.9-228.8 25 44
1-(7-Benzenesulfonyl-2,3- dihydro-benzo[1,4]dioxin-2-
ylmethyl)-aziridine 203.9-206.6 26 45
(7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-ylmethyl)-(2-
methoxy-ethyl)-amine 169.3-171.9 27 46
(7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2-ylmethyl)-
ethyl-amine 242.2-246.7 28 47 Methyl-[7-(toluene-3-sulfonyl)-
2,3-dihydro-benzo[1,4]dioxin-2- ylmethyl]-amine 99.9-106.1 29 48
Methyl-[7-(toluene-2-sulfonyl)- 2,3-dihydro-benzo[1,4]dioxin-2-
ylmethyl]-amine 169.0-170.8 30 49 1-(7-Benzenesulfonyl-2,- 3-
dihydro-benzo[1,4]dioxin-2- ylmethyl)-piperazine 279.2-279.4 31 50
N-(7-Benzenesulfonyl-2,3- dihydro-benzo[1,4]dioxin-2-
ylmethyl)-guanidine 126.5-128.3 32 51
7-Benzenesulfonyl-2,3-dihydro- benzo[1,4]dioxin-2,2'-spiro-3-
pyrrolidine 33 52 N-(7-Benzenesulfonyl-2,3-
dihydro-benzo[1,4]dioxin-- 2- ylmethyl)-N-methyl hydroxylamine
199.2-200.8 34 53 1-(7-Benzenesulfonyl-2,3-
dihydro-benzo[1,4]dioxin-2- ylmethyl)-1H-imidazole 88.0- 90.0 35 54
N-(7-Benzenesulfonyl-2,3- dihydro-benzo[1,4]dioxin-2-
ylmethyl)-acetamide 36 55 2-(3-Methylaminomethyl-2,3-
dihydro-benzo[1,4]dioxi- ne-6- sulfonyl)-benzonitrile 37 56
1-(7-Benzenesulfonyl-2,- 3- dihydro-benzo[1,4]dioxin-2-
ylmethyl)-pyrrolidin-3-ol 94.7- 96.4 38 57
3-(3-Methylaminomethyl-2,3- dihydro-benzo[1,4]dioxine-6-
sulfonyl)-benzonitrile 190.6-192.1 39 58
(7-Benzenesulfonyl-2-methyl- 2,3-dihydro-benzo[1,4]dioxin-2-
ylmethyl)-methyl-amine 40 59 (7-Benzenesulfonyl-2,3-dihyd- ro-
benzo[1,4]dioxin-2-ylmethyl)- urea 104.9-105.7 41 60
[2-(6-Benzenesulfonyl-2,3- dihydro-benzo[1,4]dioxin-2-yl)-
ethyl]-methyl-amine and [2-(7-Benzenesulfonyl-2,3-
dihydro-benzo[1,4]dioxin-2-yl)- ethyl]-methyl-amine
[0269] Synthesis
[0270] Compounds of the present invention can be made by a variety
of methods depicted in the illustrative synthetic reaction schemes
shown and described below.
[0271] The starting materials and reagents used in preparing these
compounds generally are either available from commercial suppliers,
such as Aldrich Chemical Co., or are prepared by methods known to
those skilled in the art following procedures set forth in
references such as Fieser and Fieser's Reagents for Organic
Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's
Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989,
Volumes 1-5 and Supplementals; and Organic Reactions, Wiley &
Sons: New York, 1991, Volumes 1-40. The following synthetic
reaction schemes are merely illustrative of some methods by which
the compounds of the present invention can be synthesized, and
various modifications to these synthetic reaction schemes can be
made and will be suggested to one skilled in the art having
referred to the disclosure contained in this Application.
[0272] The starting materials and the intermediates of the
synthetic reaction schemes can be isolated and purified if desired
using conventional techniques, including but not limited to,
filtration, distillation, crystallization, chromatography, and the
like. Such materials can be characterized using conventional means,
including physical constants and spectral data.
[0273] Unless specified to the contrary, the reactions described
herein preferably are conducted under an inert atmosphere at
atmospheric pressure at a reaction temperature range of from about
-78.degree. C. to about 150.degree. C., more preferably from about
0.degree. C. to about 125.degree. C., and most preferably and
conveniently at about room (or ambient) temperature, e.g., about
20.degree. C.
[0274] Scheme A below illustrates one synthetic procedure usable to
prepare compounds of the invention, wherein n, X, Ar, R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined
herein. 61
[0275] In Step 1 of Scheme A, arylsulfonyl compound a is treated
with acetyl chloride or like acyl halide, in the presence of a
Lewis acid such as aluminum trichloride, to provide an acyl
arylsulfonyl compound b. As noted above, X may be O, S or NR.sup.a,
such that arylsulfonyl compound a may be a phenol, thiophenol or
aniline compound. In embodiments wherein X is NR.sup.a and R.sup.a
is hydrogen, conventional amine protecting group techniques may be
used. Arylsulfonyl compound a may be prepared by reaction of an
arylsulfonyl halide or heteroarylsulfonyl halide with a suitably
protected phenol (where X is O), thiophenol (where X is S) or
aniline (where X is NR.sup.a), followed by deprotection. One such
preparation of an arylsulfonyl compound a is described by Sung-Eun
et al. in EP 0 514 935 B1.
[0276] In step 2, acyl arylsulfonyl compound b undergoes an
alkylation reaction with a haloalkyl cyclic oxide such as
halomethyl oxirane c to yield an arylsulfonyl methylloxirane ether
compound d. This reaction may be carried out in the presence of
mild base under polar solvent conditions.
[0277] A Bayer-Villager oxidation is carried out in step 3 by
treating compound d with a peracid such as meta-chloro perbenzoic
acid (MCPBA) or other peracid to form an aryl sulfonyl acetate
intermediate (not shown), which is treated with base such as
potassium hydroxide to effect a cyclization and afford alcohol
compound e. Compound e may be a benzodioxane where X is O, a
benzothiazine where X is S, or a benzoxazine where X is
NR.sup.a.
[0278] A mesylate compound f is formed in step 4 by treatment of
alcohol e with methane sulfonyl chloride. The reaction of step 5
may be achieved under polar aprotic solvent conditions in the
presence of a trialkylamine catalyst.
[0279] In step 5, mesylate compound f is reacted with an amine g to
afford compound h. This reaction may be carried out under polar
protic solvent conditions with heating. Compound h is a compound of
formula I in accordance with the invention.
[0280] The procedure of Scheme A provides compounds in accordance
with the invention wherein an arylsulfonyl group and an aminoalkyl
group are placed in a "meta" relationship with respect to the core
benzodioxane (or benzoxazine or benzothiazine) ring system. In
other words, an arylsulfonyl group is placed at the 7-position, and
an aminoalkyl group is placed at the 2-position, of the core ring
system. As noted above, compound h may be enantomerically pure with
respect to stereochemistry at the 2-position of the ring system
when made by the above procedure.
[0281] Many variations are possible in the procedure of Scheme A.
For example, amine g in step 5 may be a cyclic amine wherein
R.sup.1 and R.sup.2 form a ring. A cyanate may be used in stead of
amine g to react with the mesylate f to afford, after reduction of
the cyano group and necessary alkylation, compounds of formula I
with n=2. Other variations will suggest themselves to those skilled
in the art.
[0282] The procedure of Scheme A above results in a compound h
having the same stereochemistry with respect to that of halomethyl
oxirane c.
[0283] Scheme B below illustrates another synthetic procedure that
may be used in preparation of compounds of the invention, wherein
the stereochemistry of the starting materials is preserved in the
final product. In Scheme B, p, Ar, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 again are as defined herein. 62
[0284] In step 1 of Scheme B, arylsulfonylphenol i is reacted with
dioxolan tosylate j to form ether compound k. This reaction may be
carried out in the presence of potassium carbonate or like mild
base under polar, aprotic solvent conditions.
[0285] The ether compound k is hydrolyzed in step 2 to afford diol
compound l.
[0286] Using S. L. Buchwald et al. procedure, J. Am. Chem. Soc.
2001, 123, 12202-12206, diol l undergoes a cyclization in step 3 to
provide alcohol compound m.
[0287] In step 4, alcohol compound m is converted to the
corresponding mesylate n, which in turn is reacted with amine g in
step 5 in the same manner described for Scheme A above, to afford
an aminoalkyl benzodioxane compound o, which is a compound of
formula I in accordance with the invention.
[0288] Scheme C below illustrates another synthetic procedure that
may be used in preparation of compounds of the invention, wherein
p, Ar, X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6
are as defined herein. 6364
[0289] In step 1 of Scheme B, arylsulfonyl compound b is alkylated
with benzyl bromide to provide a benzyl ether compound p. As
indicated above, in embodiments wherein X is NR.sup.a, suitable
amine protecting group techniques may be employed in this step and
other steps.
[0290] In step 2, a Bayer-Villager oxidation is carried out by
treating compound p with a peracid in the manner described for step
3 of Scheme A, to form acetate compound q.
[0291] Acetate compound q is subject to base-catalyzed hydrolysis
in step 3 to remove the acetate group from compound q and provide
phenolic compound r.
[0292] In step 4, alkylation of compound r with a haloalkyl cyclic
oxide such as halomethyl oxirane c, is carried out in the manner
described for step 2 of Scheme A above, to yield a methylloxirane
ether s.
[0293] A cyclization is carried out in step 5 by debenzylation of s
to form a phenol intermediate (not shown), which then undergoes
cyclization to give alcohol compound t. Compound t may be a
benzodioxane where X is O, a benzoxathian where X is S, or a
benzoxazine where X is NR.sup.a. As in the case of Scheme A above,
the cyclization reaction of step 5 of Scheme B preserves
stereochemistry (not shown) associated with halomethyl oxirane c,
such that enantomerically pure product with respect to the
2-position of the ring system compound t is provided.
[0294] In step 6 a mesylate compound u is formed by reaction of
alcohol compound t with methane sulfonyl chloride, in the manner
described above for step 5 of Scheme A.
[0295] In step 7 of Scheme B, mesylate compound u is reacted with
an amine g to afford compound v in the manner described for step 5
of Scheme A above. Compound v is a compound of formula I in
accordance with the invention, and can be enantomerically pure with
respect to stereochemistry at the 2-position of the ring system as
related above. Alternatively, mesylate compound u may be reacted
with a cyanate to afford, after subsequent reduction and
alkylation, compounds of formula I with n=2.
[0296] Many variations are possible in the procedure of Scheme C
and will suggest themselves to those skilled in the art.
[0297] Scheme D below illustrates yet another synthetic procedure
that may be used in preparation of compounds of the invention,
wherein p, Ar, X, R.sup.1, R.sup.2, R.sup.3 and R.sup.6 are as
defined herein. In this Scheme Ar may be the same or different in
each occurrence. 65
[0298] In step 1 of Scheme D, arylsulfonylcatechol compound w is
alkylated with a diarylsulfonate x, such as a ditosylate, to give
benzodioxane y. Benzodioxane y may be a mixture of regioisomers
which may separated in this step or s subsequent step, or used
together without separation. In step 2, the protecting group P is
removed from benzodioxane y to give alcohol z. In step 3, alcohol
compound z is converted to the corresponding mesylate 1a by
reaction with methanesulfonyl chloride or like alkylsulfonyl halide
in the manner described above. Mesylate 1a in turn is reacted with
amine g in step 4 in the same manner described for 10 Scheme A
above, to afford an aminoalkyl benzodioxane compound 1b which is a
compound of formula I in accordance with the invention.
[0299] Many variations are possible in the procedure of Scheme D
and will suggest themselves to those skilled in the art.
[0300] Specific details for producing compounds of the invention
are described in the 15 Examples section below.
[0301] Utility
[0302] The compounds of the invention have selective affinity for
5-HT receptors, including the 5-HT.sub.6 the 5-HT.sub.2A receptor,
or both, and as such are expected to be useful in the treatment of
certain CNS disorders such as Parkinson's disease, Huntington's
disease, anxiety, depression, manic depression, psychosis,
epilepsy, obsessive compulsive disorders, mood disorders, migraine,
Alzheimer's disease (enhancement of cognitive memory), sleep
disorders, feeding disorders such as anorexia, bulimia, and
obesity, panic attacks, akathisia, attention deficit hyperactivity
disorder (ADHD), attention deficit disorder (ADD), withdrawal from
drug abuse such as cocaine, ethanol, nicotine and benzodiazepines,
schizophrenia, and also disorders associated with spinal trauma
and/or head injury such as hydrocephalus. Such compounds are also
expected to be of use in the treatment of certain GI
(gastrointestinal) disorders such functional bowel disorder and
irritable bowel syndrome.
[0303] Testing
[0304] The pharmacology of the compounds of this invention was
determined by art recognized procedures. The in vitro techniques
for determining the affinities of test compounds at the 5-HT6
receptor and the 5-HT2A receptor in radioligand binding and
functional assays are described below.
[0305] Administration and Pharmaceutical Composition
[0306] The invention includes pharmaceutical compositions
comprising at least one compound of the present invention, or an
individual isomer, racemic or non-racemic mixture of isomers or a
pharmaceutically acceptable salt or solvate thereof, together with
at least one pharmaceutically acceptable carrier, and optionally
other therapeutic and/or prophylactic ingredients.
[0307] In general, the compounds of the invention will be
administered in a therapeutically effective amount by any of the
accepted modes of administration for agents that serve similar
utilities. Suitable dosage ranges are typically 1-500 mg daily,
preferably 1-100 mg daily, and most preferably 1-30 mg daily,
depending upon numerous factors such as the severity of the disease
to be treated, the age and relative health of the subject, the
potency of the compound used, the route and form of administration,
the indication towards which the administration is directed, and
the preferences and experience of the medical practitioner
involved. One of ordinary skill in the art of treating such
diseases will be able, without undue experimentation and in
reliance upon personal knowledge and the disclosure of this
Application, to ascertain a therapeutically effective amount of the
compounds of the present invention for a given disease.
[0308] Compounds of the invention may be administered as
pharmaceutical formulations including those suitable for oral
(including buccal and sub-lingual), rectal, nasal, topical,
pulmonary, vaginal, or parenteral (including intramuscular,
intraarterial, intrathecal, subcutaneous and intravenous)
administration or in a form suitable for administration by
inhalation or insufflation. The preferred manner of administration
is generally oral using a convenient daily dosage regimen which can
be adjusted according to the degree of affliction.
[0309] A compound or compounds of the invention, together with one
or more conventional adjuvants, carriers, or diluents, may be
placed into the form of pharmaceutical compositions and unit
dosages. The pharmaceutical compositions and unit dosage forms may
be comprised of conventional ingredients in conventional
proportions, with or without additional active compounds or
principles, and the unit dosage forms may contain any suitable
effective amount of the active ingredient commensurate with the
intended daily dosage range to be employed. The pharmaceutical
compositions may be employed as solids, such as tablets or filled
capsules, semisolids, powders, sustained release formulations, or
liquids such as solutions, suspensions, emulsions, elixirs, or
filled capsules for oral use; or in the form of suppositories for
rectal or vaginal administration; or in the form of sterile
injectable solutions for parenteral use. Formulations containing
about one (1) milligram of active ingredient or, more broadly,
about 0.01 to about one hundred (100) milligrams, per tablet, are
accordingly suitable representative unit dosage forms.
[0310] The compounds of the invention may be formulated in a wide
variety of oral administration dosage forms. The pharmaceutical
compositions and dosage forms may comprise a compound or compounds
of the present invention or pharmaceutically acceptable salts
thereof as the active component. The pharmaceutically acceptable
carriers may be either solid or liquid. Solid form preparations
include powders, tablets, pills, capsules, cachets, suppositories,
and dispersible granules. A solid carrier may be one or more
substances which may also act as diluents, flavouring agents,
solubilizers, lubricants, suspending agents, binders,
preservatives, tablet disintegrating agents, or an encapsulating
material. In powders, the carrier generally is a finely divided
solid which is a mixture with the finely divided active component.
In tablets, the active component generally is mixed with the
carrier having the necessary binding capacity in suitable
proportions and compacted in the shape and size desired. The
powders and tablets preferably contain from about one (1) to about
seventy (70) percent of the active compound. Suitable carriers
include but are not limited to magnesium carbonate, magnesium
stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine,
tragacanth, methylcellulose, sodium carboxymethylcellulose, a low
melting wax, cocoa butter, and the like. The term "preparation" is
intended to include the formulation of the active compound with
encapsulating material as carrier, providing a capsule in which the
active component, with or without carriers, is surrounded by a
carrier, which is in association with it. Similarly, cachets and
lozenges are included. Tablets, powders, capsules, pills, cachets,
and lozenges may be as solid forms suitable for oral
administration.
[0311] Other forms suitable for oral administration include liquid
form preparations including emulsions, syrups, elixirs, aqueous
solutions, aqueous suspensions, or solid form preparations which
are intended to be converted shortly before use to liquid form
preparations. Emulsions may be prepared in solutions, for example,
in aqueous propylene glycol solutions or may contain emulsifying
agents, for example, such as lecithin, sorbitan monooleate, or
acacia. Aqueous solutions can be prepared by dissolving the active
component in water and adding suitable colorants, flavors,
stabilizers, and thickening agents. Aqueous suspensions can be
prepared by dispersing the finely divided active component in water
with viscous material, such as natural or synthetic gums, resins,
methylcellulose, sodium carboxymethylcellulose, and other well
known suspending agents. Solid form preparations include solutions,
suspensions, and emulsions, and may contain, in addition to the
active component, colorants, flavors, stabilizers, buffers,
artificial and natural sweeteners, dispersants, thickeners,
solubilizing agents, and the like.
[0312] The compounds of the invention may be formulated for
parenteral administration (e.g., by injection, for example bolus
injection or continuous infusion) and may be presented in unit dose
form in ampoules, pre-filled syringes, small volume infusion or in
multi-dose containers with an added preservative. The compositions
may take such forms as suspensions, solutions, or emulsions in oily
or aqueous vehicles, for example solutions in aqueous polyethylene
glycol. Examples of oily or nonaqueous carriers, diluents, solvents
or vehicles include propylene glycol, polyethylene glycol,
vegetable oils (e.g., olive oil), and injectable organic esters
(e.g., ethyl oleate), and may contain formulatory agents such as
preserving, wetting, emulsifying or suspending, stabilizing and/or
dispersing agents. Alternatively, the active ingredient may be in
powder form, obtained by aseptic isolation of sterile solid or by
lyophilization from solution for constitution before use with a
suitable vehicle, e.g., sterile, pyrogen-free water.
[0313] The compounds of the invention may be formulated for topical
administration to the epidermis as ointments, creams or lotions, or
as a transdermal patch. Ointments and creams may, for example, be
formulated with an aqueous or oily base with the addition of
suitable thickening and/or gelling agents. Lotions may be
formulated with an aqueous or oily base and will in general also
containing one or more emulsifying agents, stabilizing agents,
dispersing agents, suspending agents, thickening agents, or
coloring agents. Formulations suitable for topical administration
in the mouth include lozenges comprising active agents in a
flavored base, usually sucrose and acacia or tragacanth; pastilles
comprising the active ingredient in an inert base such as gelatine
and glycerine or sucrose and acacia; and mouthwashes comprising the
active ingredient in a suitable liquid carrier.
[0314] The compounds of the invention may be formulated for
administration as suppositories. A low melting wax, such as a
mixture of fatty acid glycerides or cocoa butter is first melted
and the active component is dispersed homogeneously, for example,
by stirring. The molten homogeneous mixture is then poured into
convenient sized molds, allowed to cool, and to solidify.
[0315] The compounds of the invention may be formulated for vaginal
administration. Pessaries, tampons, creams, gels, pastes, foams or
sprays containing in addition to the active ingredient such
carriers as are known in the art to be appropriate.
[0316] The subject compounds may be formulated for nasal
administration. The solutions or suspensions are applied directly
to the nasal cavity by conventional means, for example, with a
dropper, pipette or spray. The formulations may be provided in a
single or multidose form. In the latter case of a dropper or
pipette, this may be achieved by the patient administering an
appropriate, predetermined volume of the solution or suspension. In
the case of a spray, this may be achieved for example by means of a
metering atomizing spray pump.
[0317] The compounds of the invention may be formulated for aerosol
administration, particularly to the respiratory tract and including
intranasal administration. The compound will generally have a small
particle size for example of the order of five (5) microns or less.
Such a particle size may be obtained by means known in the art, for
example by micronization. The active ingredient is provided in a
pressurized pack with a suitable propellant such as a
chlorofluorocarbon (CFC), for example, dichlorodifluoromethane,
trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon
dioxide or other suitable gas. The aerosol may conveniently also
contain a surfactant such as lecithin. The dose of drug may be
controlled by a metered valve. Alternatively the active ingredients
may be provided in a form of a dry powder, for example a powder mix
of the compound in a suitable powder base such as lactose, starch,
starch derivatives such as hydroxypropylmethyl cellulose and
polyvinylpyrrolidine (PVP). The powder carrier will form a gel in
the nasal cavity. The powder composition may be presented in unit
dose form for example in capsules or cartridges of e.g., gelatine
or blister packs from which the powder may be administered by means
of an inhaler.
[0318] When desired, formulations can be prepared with enteric
coatings adapted for sustained or controlled release administration
of the active ingredient. For example, the compounds of the present
invention can be formulated in transdermal or subcutaneous drug
delivery devices. These delivery systems are advantageous when
sustained release of the compound is necessary and when patient
compliance with a treatment regimen is crucial. Compounds in
transdermal delivery systems are frequently attached to an
skin-adhesive solid support. The compound of interest can also be
combined with a penetration enhancer, e.g., Azone
(1-dodecylazacycloheptan-2-one). Sustained release delivery systems
are inserted subcutaneously into the subdermal layer by surgery or
injection. The subdermal implants encapsulate the compound in a
lipid soluble membrane, e.g., silicone rubber, or a biodegradable
polymer, e.g., polylactic acid.
[0319] The pharmaceutical preparations are preferably in unit
dosage forms. In such form, the preparation is subdivided into unit
doses containing appropriate quantities of the active component.
The unit dosage form can be a packaged preparation, the package
containing discrete quantities of preparation, such as packeted
tablets, capsules, and powders in vials or ampoules. Also, the unit
dosage form can be a capsule, tablet, cachet, or lozenge itself, or
it can be the appropriate number of any of these in packaged
form.
[0320] Other suitable pharmaceutical carriers and their
formulations are described in Remington: The Science and Practice
of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company,
19th edition, Easton, Pa. Representative pharmaceutical
formulations containing a compound of the present invention are
described below.
EXAMPLES
[0321] The following preparations and examples are given to enable
those skilled in the art to more clearly understand and to practice
the present invention. They should not be considered as limiting
the scope of the invention, but merely as being illustrative and
representative thereof.
Example 1
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl-ami-
ne
[0322] The synthetic procedure of Example 1 is outlined in Scheme D
below. 66
[0323] Step1
10(5-Benzenesulfonyl-2-hydroxy-phenyl)-ethanone
[0324] 67
[0325] The 4-benzenesulfonyl-phenol used in step 1 was prepared
according to the procedure described by Sung-Eun et al. in EP 0 514
935 B1, by treating anisole with benzensulfonyl chloride in the
presence of AlCl.sub.3, and treating the resulting compound with
HB.sub.r in acetic acid under reflux to afford
4-benzenesulfonyl-phenol.
[0326] Chloroacetyl chloride (2.35 g; 0.030 mol) was added at
0.degree. C. to a solution of 4-benzenesulfonyl-phenol (2.34 g;
0.010 mol) in carbon disulfide (50 mL). After 10 minutes at ambient
temperature, aluminum trichloride was added in small portions. The
reaction was heated at 130.degree. C. under reflux, and the carbon
disulfide was distilled, after which the reaction was heated at
180.degree. C. for 45 minutes. After cooling to ambient
temperature, the mixture was treated with 10% aqueous HCl (25 mL),
extracted with ethyl acetate (100 mL.times.2), dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The solid residue was
purified by column chromatography on silica gel (hexane-ethyl
acetate; 7:3) to give
1-(5-benzenesulfonyl-2-hydroxy-phenyl)-ethanone as a white solid
(1.924 g; 70%). A sample was recrystallized from ethyl
acetate-hexane: MS; (M).sup.+ 276, m. p. 155.5-157.3.degree. C.
[0327] Similarly,
1-[5-(3-Fluoro-benzenesulfonyl)-2-hydroxy-phenyl]-ethano- ne was
prepared: M.p. 164.5-165.1.degree. C.
[0328] Step 2
1-(5-Benzenesulfonyl-2-(S)-oxiranylmethoxy-phenyl)-ethanone
[0329] 68
[0330] (R)-(-)Epichlorhydrin (1.93 g; 0.021 mol) was added to a
suspension of 1-(5-benzenesulfonyl-2-hydroxy-phenyl)-ethanone (1.92
g; 0.007 mol) and potassium carbonate (1.44 g; 0.011 mol) in
acetonitrile (5 mL). The mixture was heated under reflux for 18
hours. After cooling to ambient temperature, the mixture was
diluted with ethyl acetate, filtered, washed with water and
saturated sodium bicarbonate, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The crude material was purified by flash
chromatography on silica gel (hexane-ethyl acetate; 7:3) to give
1-(5-benzene sulfonyl-2-(S)-oxiranylmethoxy-phenyl)-ethanone as a
white solid (1.456 g; 63%). A sample was recrystallized from
diethyl ether-hexane: M.p. 115.1-116.8.degree. C. Similarly, but
replacing (R)-(-)epichlorhydrin with (S)-(+)epichlorhydrin,
1-(5-benzene sulfonyl-2-(R)-oxiranylmethoxy-phenyl)-ethanone was
prepared. M.p. 111.9-113.5.degree. C. Similarly, but replacing
1-(5-benzenesulfonyl-2-hy- droxy-phenyl)-ethanone with
1-[5-(3-fluoro-benzenesulfonyl)-2-hydroxy-phen- yl]-ethanone, the
above procedure gave 1-[5-(3-fluoro-benzenesulfonyl)-2-(-
S)-oxiranylmethoxy-phenyl]-ethanone: M.p. 112.7-114.9.degree. C.
Replacing 1-(5-benzenesulfonyl-2-hydroxy-phenyl)-ethanone with
1-[5-(3-Fluoro-benzenesulfonyl)-2-hydroxy-phenyl]-ethanone and
replacing (R)-(-)epichlorhydrin with (S)-(+)epichlorhydrin gave
1-[5-(3-Fluoro-benzenesulfonyl)-2-(R)-oxiranylmethoxy-phenyl]-ethanone.
M.p. 118.3-120.5.degree. C.
[0331] Step 3
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-yl)-methanol
[0332] 69
[0333] A solution of
1-(5-benzenesulfonyl-2-(S)-oxiranylmethoxy-phenyl)-et- hanone (2.04
g; 0.059 mol) and meta-chloroperoxybenzoic acid (4.13 g; 0.018 mol,
max. 77%) in chloroform (20 mL) was heated under reflux for 18
hours. After cooling to ambient temperature the mixture was diluted
with chloroform, filtered, washed with water and saturated sodium
bicarbonate, dried (Na.sub.2SO.sub.4) and concentrated in vacuo.
This crude residue (0.85 g; 0.0024 mol) dissolved in methanol (5
mL) was added to a solution of 10% aqueous potassium hydroxide (4
mL) at 0.degree. C. The mixture was stirred for 30 minutes at room
temperature. Solvent was removed in vacuo, and the residue was
dissolve in ethyl acetate, washed with 10% aqueous hydrochloric
acid followed by saturated brine, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo to give
(7-benzenesulfonyl-2,3-dihydro-benzo[1,- 4]dioxin-2(R)-yl)-methanol
as an oil (1.44 g; 77%): MS (M+H).sup.+ 307.
[0334] Step 4
Methanesulfonic acid
7-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-- ylmethyl
ester
[0335] 70
[0336] Methanesulfonyl chloride (0.550 g; 0.0048 mol) at 0.degree.
C. was added drop-wise to a solution of
(7-benzenesulfonyl-2,3-dihydro-benzo[1,4- ]dioxin-2(R)-yl)-methanol
(0.73 g; 0.00238 mol) and triethyl amine (0.48 g; 0.0048 mol) in
dichloromethane (10 mL). The mixture was stirred at 0.degree. C.
for 45 minutes, and then diluted with dichloromethane (20 mL),
washed with water, dried (Na.sub.2SO.sub.4) and concentrated in
vacuo. The crude material was purified by flash chromatography on
silica gel (hexane-ethyl acetate; 1:1) to give methansulfonic acid
7-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2(S)-yl-methyl ester
as a foam (0.67 g; 73%): MS (M+H).sup.+ 385.
[0337] Step 5
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl-ami-
ne
[0338] 71
[0339] A 2M solution of methyl amine in methanol (10 mL) and
methansulfonic acid
7-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2(S)-y- l-methyl
ester (0.87 g, 2.26 mmol) were heated in a microwave at 100.degree.
C. for 3 hours. The solvent was removed under reduced pressure and
the crude material was purified by flash chromatography on silica
gel (eluting with dichloromethane--methanol; 98:2, v/v) to give
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2(R)-ylmethyl)-methyl-ami-
ne as a white solid (0.557 g; 77%), which was converted to a
hydrochloride salt: MS (M).sup.+ 319; m.p. 240.0-243.6.degree. C.,
[.alpha.]=+40.5.degree. (methanol; c=1).
[0340] Similarly prepared were:
[0341]
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2(S)-ylmethyl)-meth-
yl-amine hydrochloride salt: MS (M).sup.+ 319; m.p.
247.1-249.9.degree. C., [.alpha.]=-40.degree. (methanol; c=1);
[0342]
[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro-benzo[1,4]dioxin-2(R)-ylm-
ethyl]-methyl-amine hydrochloride salt: MS (M+H).sup.+ 338; m.p.
245.8-246.4.degree. C., [.alpha.]=+40.degree. (methanol; c=0.5);
and
[0343]
[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro-benzo[1,4]dioxin-2(S)-ylm-
ethyl]-methyl-amine hydrochloride salt: MS (M+H).sup.+ 338; m.p.
249.0-250.9.degree. C., [.alpha.]=-40.degree. (methanol;
c=0.5).
Example 2
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl-ami-
ne
[0344] Example 2 provides an alternate procedure for preparation of
(7-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl-am-
ine, and is outlined in Scheme E below. 72
[0345] Step 1
4-(S)-(4-Benzenesulfonyl-2-bromo-phenoxymethyl)-2,2-dimethy-[3,3]dioxolan
[0346] 73
[0347] Toluene-4-(R)-sulfonic acid
2,2-dimethyl-[1,3]dioxolan-4-yl-methyl ester (0.99 g; 0.003 mol)
was added to a suspension of 4-benzenesulfonyl-2-bromo-phenol (0.91
g; 0.003 mol, prepared by the procedure of Sung-Eun et al. as
described in Example 1) and potassium carbonate (0.88 g; 0.0006
mol) in acetonitrile (4 mL). The mixture was heated under reflux
for 72 hours. After cooling to ambient temperature the mixture was
diluted with ethyl acetate, filtered, washed with water and
saturated sodium bicarbonate, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The crude material was purified by
crystallization from diethyl ether-hexane to give
4-(S)-(4-benzenesulfonyl-2-bromo-phenox-
ymethyl)-2,2-dimethy-[3,3]dioxolan as a white crystalline (1.41 g;
84%). Mp. 115.8-118.5.degree. C., [.alpha.]=+20.2.degree.
(methanol; c=1).
[0348] Step 2
3-(4-Benzenesulfonyl-2-bromo-phenoxy)-propane 1-2-(R)-diol
[0349] 74
[0350] A solution of
4-(S)-(4-benzenesulfonyl-2-bromo-phenoxymethyl)-2,2-d-
imethyl-[3,3]dioxolan (1.07 g, 0.0025 mol) and pyridinum
toluene-4-sulfonate (0.38 g, 0.0015 mol) in acetone (20 mL) and
water (5 mL) was heated under reflux for 12 hours. The solvent was
removed under reduced pressure. The oily residue was dissolved in
ethyl acetate (100 mL), washed with cold 10% aqueous hydrochloric
acid, saturated sodium bicarbonate, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. Recrystallization of the residue (diethyl
ether-hexane) gave 3-(4-benzenesulfonyl-2-bromo-phenoxy)-propane
1-2-(R)-diol as white crystals. Mp. 104.6-105.9.degree. C.
[0351] Step 3
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-yl)-methanol
[0352] 75
[0353] A suspension of
3-(4-benzenesulfonyl-2-bromo-phenoxy)-propane 1-2-(R)-diol (0.390
g, 0.001 mol), Pd(OAc).sub.2 (0.007 g, 0.00003 mol, 3 mol %),
racemic-2-(di-t-butylphosphino)-1,1'-binaphthyl (0.012 g, 0.00003,
3 mol %) and K.sub.3PO.sub.4 (0.320 g, 0.0015, 1.5 equiv) in
toluene (1 mL) was heated under argon atmosphere at 80.degree. C.
for 5 hours. After cooling to ambient temperature the mixture was
diluted with ethyl acetate (1 mL), washed with water and saturated
sodium chloride, dried (Na.sub.2SO.sub.4) and concentrated in
vacuo. The crude material was purified by flash chromatography on
silica gel (eluting with hexane-ethyl acetate; 1:1, v/v) to give
(7-benzenesulfonyl-2,3-dihydro-be- nzo[1,4]dioxin-2(R)-yl)-methanol
as an oil which solidified upon standing. (0.160 g; 52%). M.p.
112.0-113.5.degree. C., [.alpha.]=+36.7.degree. (CHCl.sub.3,
c=1).
[0354] Step 4
Methanesulfonic acid
7-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-- ylmethyl
ester
[0355] 76
[0356] Using the procedure of step 4 of example 1, methanesulfonic
acid 7-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-ylmethyl
ester was prepared: MS ;+H).sup.+ 385.
[0357] Step 5
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl-ami-
ne
[0358] 77
[0359] Using the procedure of step 5 of example 1,
(7-benzenesulfonyl-2,3--
dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl amine was prepared
as a hydrochloride salt: MS; (M+H).sup.+ 320, m.p.
218.2-220.5.degree. C., [.alpha.]=+49.degree. (methanol; c=1).
Example 3
(6-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-ylmethyl)-methyl-ami-
ne
[0360] The synthetic procedure of Example 3 is outlined in Scheme F
below. 7879
[0361] Step 1
1-(5-Benzenesulfonyl-2-benzyloxy-phenyl)-ethanone
[0362] 80
[0363] Benzyl bromide (1.443 g; 0.0087 mol) was added to a
suspension of 1-(5-benzenesulfonyl-2-hydroxy-phenyl)-ethanone (2.01
g; 0.0073 mol) and potassium carbonate (2.01 g; 0.015 mol) in
acetonitrile (5.0 mL). The mixture was heated under reflux for 18
hours. After cooling to ambient temperature, the mixture was
diluted with ethyl acetate, filtered, washed with water and
saturated sodium bicarbonate, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The crude material was purified by flash
chromatography on silica gel (hexane-ethyl acetate; 7:3) to give
1-(5-benzenesulfonyl-2-benzyloxy-phenyl)-ethanone as a white solid
(2.17 g; 81%). A sample was recrystallized from diethyl
ether-hexane: M.p. 80.5-82.4.degree. C.
[0364] Step 2
Acetic acid 5-benzenesulfonyl-2-benzyloxy-phenyl ester
[0365] 81
[0366] A solution of
1-(5-benzenesulfonyl-2-benzyloxy-phenyl)-ethanone (2.16 g; 0.059
mol) and meta-chloroperoxybenzoic acid (3.98 g; 0.018 mol, max.
77%) in chloroform (20 mL) was heated under reflux for 18 hours.
After cooling to ambient temperature the mixture was diluted with
chloroform, filtered, washed with water and saturated sodium
bicarbonate, dried (Na.sub.2SO.sub.4) and concentrated in vacuo.
The crude material was purified by flash chromatography on silica
gel (hexane-ethyl acetate; 1:1) to give acetic acid
5-benzenesulfonyl-2-benzyloxy-phenyl ester (2.1 g; 93%): M.p.
106.9-111.1.degree. C.
[0367] Step 3
5-Benzenesulfonyl-2-benzyloxy-phenol
[0368] 82
[0369] A solution of 10% aqueous potassium hydroxide (4 mL) at
0.degree. C. was added to a solution of
5-benzenesulfonyl-2-benzyloxy-phenyl ester (1.18 g; 0.0031 mol) in
methanol (5 mL), and the mixture was stirred for 30 minutes at room
temperature. Solvent was removed in vacuo, and the residue was
dissolve in ethyl acetate, washed with 10% aqueous hydrochloric
acid, washed with brine, dried (Na.sub.2SO.sub.4) and concentrated
in vacuo to give 5-benzenesulfonyl-2-benzyloxy-phenol as a white
solid (0.865 g; 82.4%). A sample was recrystallized from diethyl
ether: MS; (M-H).sup.- 339; m.p. 144.5-147.8.degree. C.
[0370] Step 4
2-(S)-(5-Benzenesulfonyl-2-benzyloxymethyl)-oxirane
[0371] 83
[0372] Follow the procedure of step 2 of Example 1 above,
2-(S)-(5-benzenesulfonyl-2-benzyloxymethyl)-oxirane was prepared:
MS (M+H).sup.+ 397.
[0373] Similarly,
2-(R)-(5-benzenesulfonyl-2-benzyloxymethyl)-oxirane was
prepared:
[0374] MS (M+H).sup.+ 397.
[0375] Step 5
(6-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-(R)-2-yl)-methanol
[0376] 84
[0377] A mixture of
2-(S)-(5-benzenesulfonyl-2-benzyloxymethyl)-oxirane (0.29 g; 0.73
mmol), potassium formate (0.307 g; 0.0036 mol) and 10% palladium on
charcoal (0.002 g) in ethanol (5 mL) was heated under reflux for 30
min. After cooling to ambient temperature the mixture was diluted
with ethyl acetate and filtered through celite. The filtrate was
washed with water, saturated sodium chloride, dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The crude material
was purified by flash chromatography on silica gel (eluting with
hexane-ethyl acetate; 1:1, v/v) to give
(6-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-yl)-me-
thanol as an oil which solidified upon standing. (0.155 g; 69%); MS
(M+H).sup.+ 307.
[0378] Similarly,
(6-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-yl-
)-methanol was prepared.
[0379] Step 6
Methanesulfonic acid
6-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-- ylmethyl
ester
[0380] 85
[0381] Using the procedure of step 4 of example 1, methanesulfonic
acid 6-benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(S)-ylmethyl
ester was prepared: MS (M+H).sup.+ 385.
[0382] Similarly, methanesulfonic acid
6-benzenesulfonyl-2,3-dihydro-benzo- [1,4]dioxin-2-(R)-ylmethyl
ester was prepared.
[0383] Step 7
(6-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl
amine
[0384] 86
[0385] Using the procedure of step 5 of example 1,
(6-benzenesulfonyl-2,3--
dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl amine was prepared
as a hydrochloride salt: MS; (M+H).sup.+ 320, m.p.
218.2-220.5.degree. C., [.alpha.]=+45.degree. (methanol; c=1).
[0386] Following the same procedure,
(6-benzenesulfonyl-2,3-dihydro-benzo[-
1,4]dioxin-2-(S)-yl-methyl)-methyl amine hydrochloride salt was
also prepared: MS; (M+H).sup.+ 320, m.p. 209.0-212.0.degree. C.,
[.alpha.]=-44.degree. (methanol; c=0.5).
Example 4
[0387] Formulations
[0388] Pharmaceutical preparations for delivery by various routes
are formulated as shown in the following Tables. "Active
ingredient" or "Active compound" as used in the Tables means one or
more of the Compounds of Formula I.
2 Composition for Oral Administration Ingredient % wt./wt. Active
ingredient 20.0% Lactose 79.5% Magnesium stearate 0.5%
[0389] The ingredients are mixed and dispensed into capsules
containing about 100 mg each; one capsule would approximate a total
daily dosage.
3 Composition for Oral Administration Ingredient % wt./wt. Active
ingredient 20.0% Magnesium stearate 0.5% Crossearmellose sodium
2.0% Lactose 76.5% PVP (polyvinylpyrrolidine) 1.0%
[0390] The ingredients are combined and granulated using a solvent
such as methanol. The formulation is then dried and formed into
tablets (containing about 20 mg of active compound) with an
appropriate tablet machine.
4 Composition for Oral Administration Ingredient Amount Active
compound 1.0 g Fumaric acid 0.5 g Sodium chloride 2.0 g Methyl
paraben 0.15 g Propyl paraben 0.05 g Granulated sugar 25.5 g
Sorbitol (70% solution) 12.85 g Veegum K (Vanderbilt Co.) 1.0 g
Flavoring 0.035 ml Colorings 0.5 mg Distilled water q.s. to 100
ml
[0391] The ingredients are mixed to form a suspension for oral
administration.
5 Parenteral Formulation Ingredient % wt./wt. Active ingredient
0.25 g Sodium Chloride qs to make isotonic Water for injection 100
ml
[0392] The active ingredient is dissolved in a portion of the water
for injection. A sufficient quantity of sodium chloride is then
added with stirring to make the solution isotonic. The solution is
made up to weight with the remainder of the water for injection,
filtered through a 0.2 micron membrane filter and packaged under
sterile conditions.
6 Suppository Formulation Ingredient % wt./wt. Active ingredient
1.0% Polyethylene glycol 1000 74.5% Polyethylene glycol 4000
24.5%
[0393] The ingredients are melted together and mixed on a steam
bath, and poured into molds containing 2.5 g total weight.
7 Topical Formulation Ingredients grams Active compound 0.2-2 Span
60 2 Tween 60 2 Mineral oil 5 Petrolatum 10 Methyl paraben 0.15
Propyl paraben 0.05 BHA (butylated hydroxy anisole) 0.01 Water q.s.
100
[0394] All of the ingredients, except water, are combined and
heated to about 60.degree. C. with stirring. A sufficient quantity
of water at about 60.degree. C. is then added with vigorous
stirring to emulsify the ingredients, and water then added q.s.
about 100 g.
Nasal Spray Formulations
[0395] Several aqueous suspensions containing from about 0.025-0.5
percent active compound are prepared as nasal spray formulations.
The formulations optionally contain inactive ingredients such as,
for example, microcrystalline cellulose, sodium
carboxymethylcellulose, dextrose, and the like. Hydrochloric acid
may be added to adjust pH. The nasal spray formulations may be
delivered via a nasal spray metered pump typically delivering about
50-100 microliters of formulation per actuation. A typical dosing
schedule is 2-4 sprays every 4-12 hours.
Example 5
[0396] Radioligand Binding Studies
[0397] This example illustrates in vitro radioligand binding
studies of compound of formula I.
[0398] The binding activity of compounds of this invention in vitro
was determined as follows. Duplicate determinations of 5-HT.sub.6
ligand affinity were made by competing for binding of [.sup.3H]LSD
in cell membranes derived from HEK293 cells stably expressing
recombinant human 5-HT.sub.6 receptor. Duplicate determinations of
5-HT.sub.2A ligand affinity were made by competing for binding of
[.sup.3H]Ketanserin
(3-(2-(4-(4-fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione)
in cell membranes derived from CHO--K1 cells stably expressing
recombinant human 5-HT.sub.2A receptor. Membranes were prepared
from HEK 293 cell lines by the method described by Monsma et al.,
Molecular Pharmacology, Vol. 43 pp. 320-327 (1993), and from
CHO--K1 cell lines as described by Bonhaus et al., Br J Pharmacol.
June;1 15(4):622-8 (1995).
[0399] For estimation of affinity at the 5-HT.sub.6 receptor, all
determinations were made in assay buffer containing 50 mM Tris-HCl,
10 mM MgSO.sub.4, 0.5 mM EDTA, 1 mM ascorbic acid, pH 7.4 at
37.degree. C., in a 250 microliter reaction volume. For estimation
of affinity at the 5-HT.sub.2A receptor all determinations were
made in assay buffer containing 50 mM Tris-HCl, 5 mM ascorbic acid,
4 mM CaCl2, pH 7.4 at 32.degree. C., in a 250 microliter reaction
volume.
[0400] Assay tubes containing [.sup.3H] LSD or [.sup.3H]Ketanserin
(5 nM), competing ligand, and membrane were incubated in a shaking
water bath for 75 min. at 37.degree. C. (for 5-HT.sub.6) or 60 min.
at 32.degree. C. (for 5-HT.sub.2A), filtered onto Packard GF-B
plates (pre-soaked with 0.3% PEI) using a Packard 96 well cell
harvester and washed 3 times in ice cold 50 mM Tris-HCl. Bound
[.sup.3H] LSD or [.sup.3H]Ketanserin were determined as radioactive
counts per minute using Packard TopCount.
[0401] Displacement of [.sup.3H]LSD or [.sup.3H]Ketanserin from the
binding sites was quantified by fitting concentration-binding data
to a 4-parameter logistic equation: 1 binding = basal + ( B max -
basal 1 + 10 - Hill ( log [ ligand ] - log IC 50 )
[0402] where Hill is the Hill slope, [ligand] is the concentration
of competing radioligand and IC.sub.50 is the concentration of
radioligand producing half-maximal specific binding of radioligand.
The specific binding window is the difference between the Bmax and
the basal parameters. Using the procedures of this Example,
compounds of Formula I were tested and found to be selective
5-HT.sub.6 antagonists, selective 5-HT.sub.2A antagonists, or both.
For example, the compound
(7-Benzenesulfonyl-2,3-dihydro-benzo[1,4]dioxin-2-(R)-ylmethyl)-methyl-am-
ine exhibted a pKi of approximately 9.78 for the 5-HT6 receptor,
and
[7-(3-Fluoro-benzenesulfonyl)-2,3-dihydro-benzo[1,4]dioxin-2-(S)-ylmethyl-
]-methyl-amine exhibted a pKi of approximately 7.74 for the 5-HT2A
receptor.
Example 6
[0403] Cognition Enhancement
[0404] The cognition-enhancing properties of compounds of the
invention may be in a model of animal cognition: the object
recognition task model. 4-month-old male Wistar rats (Charles
River, The Netherlands) were used. Compounds were prepared daily
and dissolved in physiological saline and tested at three doses.
Administration was always given i.p. (injection volume 1 ml/kg) 60
minutes before T1. Scopolamine hydrobromide was injected 30 minutes
after compound injection. Two equal testing groups were made of 24
rats and were tested by two experimenters. The testing order of
doses was determined randomly. The experiments were performed using
a double blind protocol. All rats were treated once with each dose
condition. The object recognition test was performed as described
by Ennaceur, A., Delacour, J., 1988, A new one-trial test for
neurobiological studies of memory in rats. 1: Behavioral data.
Behav. Brain Res. 31, 47-59.
[0405] While the present invention has been described with
reference to the specific embodiments thereof, it should be
understood by those skilled in the art that various changes may be
made and equivalents may be substituted without departing from the
true spirit and scope of the invention. In addition, many
modifications may be made to adapt a particular situation,
material, composition of matter, process, process step or steps, to
the objective, spirit and scope of the present invention. All such
modifications are intended to be within the scope of the claims
appended hereto.
* * * * *